{
  "items": [
    {
      "id": "wkrGn28v",
      "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Jul 2, 2025 10:19am",
      "snippet": "In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "E9KnfVkc",
      "url": "https://www.fiercepharma.com/pharma/amgens-chemocentryx-prevails-investor-lawsuit-around-autoimmune-drug-tavneos",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 19, 2025 9:58am",
      "snippet": "Dogged for several years by an investor lawsuit accusing the company of misleading investors about the safety and efficacy of its now-approved drug Tavneos, ChemoCentryx has emerged victorious in a securities fraud complaint.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "NuL2YO87",
      "url": "https://www.fiercepharma.com/biotech/csl-lay-15-workforce-cut-rd-costs-and-spin-out-vaccine-unit",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 19, 2025 4:33am",
      "snippet": "CSL is laying off up to 15% of its workforce as the company looks to cut R&amp;D costs and spin out its vaccine subsidiary.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "cmAQkVRF",
      "url": "https://www.fiercepharma.com/pharma/sarepta-shares-more-elevidys-safety-data-response-patient-group-fda-petition",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 10:56am",
      "snippet": "Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy patient group petitions the FDA to update the medicine’s label.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "39MdEmWV",
      "url": "https://www.fiercepharma.com/pharma/vanda-scores-landmark-win-over-fda-years-long-dispute-over-hetlioz-jet-lag-disorder-bid",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 11:05am",
      "snippet": "An appeals court overturned a prior FDA action in a years-long face-off between Vanda and the agency over a delayed hearing for Vanda's jet lag disorder hopeful Hetlioz.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "obQiuMuC",
      "url": "https://www.fiercepharma.com/marketing/novo-nordisk-unveils-499-cash-pay-ozempic-offering-amid-continued-compounder-competition",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 11:02am",
      "snippet": "Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for a monthly supply of Wegovy, Novo Nordisk is expanding the discount to its other GLP-1 heavyweight.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "wEapQErW",
      "url": "https://www.fiercepharma.com/pharma/conflicts-interests-cdcs-vaccine-panel-historic-low-when-rfk-jrs-hhs-purged-committee-remove",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 2:02pm",
      "snippet": "Earlier this summer, HHS Secretary Robert F. Kennedy ousted all members of the CDC's vaccine advisory committee in an effort to remove industry influence. But according to a new study, industry-related conflicts of influence had already been \"virtually eliminated\" for years.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ggwcuujR",
      "url": "https://www.fiercepharma.com/pharma/novos-wegovy-picks-3rd-indication-fda-approval-severe-liver-disease-mash",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 18, 2025 9:43am",
      "snippet": "The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis. The green light tees up a likely showdown with Madrigal Pharmaceuticals' approved drug Rezdiffra in the severe form of fatty liver diseas",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "r8f2E2W9",
      "url": "https://www.fiercepharma.com/sponsored/ai-media-and-evolution-omnichannel-healthcare-marketing-ray-rosti-episode-3-next",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 6, 2025 3:50pm",
      "snippet": "Klick Media’s President shares his perspective on how AI is redefining planning, analytics and micro-segmentation in HCP marketing",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "sq_FYhOq",
      "url": "https://www.fiercepharma.com/sponsored/fedegaris-fob5-redefines-sterilization-compact-design-and-full-gmp-compliance",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 13, 2025 9:58am",
      "snippet": "Discover how Fedegari’s FOB5 is redefining sterilization with compact design, GMP compliance &amp; high-containment capabilities.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6500000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 2,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "8srYTDkS",
      "url": "https://www.fiercepharma.com/pharma/fiercest-women-life-sciences-2025-nominations-open-now",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 12:13pm",
      "snippet": "Every year, Fierce celebrates women making a powerful impact across biopharma and medtech. It’s time once again to make your suggestions for this year’s honorees.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Q47GYJPj",
      "url": "https://www.fiercepharma.com/pharma/tonixs-tonmya-gains-fda-nod-becoming-first-new-fibromyalgia-treatment-more-16-years",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 4:57pm",
      "snippet": "Tonix Pharmaceuticals was founded in 2010 to develop and bring to market a drug for fibromyalgia. Fifteen years later, the New Jersey company has accomplished its mission with an FDA sign-off for Tonmya.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "hf_-AEV3",
      "url": "https://www.fiercepharma.com/pharma/lundbeck-dials-migraine-drug-us-peak-sales-stays-positive-rexulti-ptsd-use",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 10:09am",
      "snippet": "After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U.S., Lundbeck has raised its peak sales projection for the therapy in the key market.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Q5dhOn4c",
      "url": "https://www.fiercepharma.com/pharma/amgen-skirts-50m-payout-blincyto-patent-litigation-tiff-lindis",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 9:55am",
      "snippet": "U.S. District Judge Gregory Williams concluded that two patents held by Lindis Biotech “are unenforceable due to inequitable conduct.” The decision negates the $50.3 million jury verdict Lindis won in December over allegations that Amgen’s Blincyto violated Lindis-held intellectu",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5NU13kkc",
      "url": "https://www.fiercepharma.com/marketing/astrazeneca-begins-dtc-home-delivery-self-administered-flumist-vaccine",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 10:06am",
      "snippet": "Nearly a year after earning the first-ever FDA approval for a self-administered flu vaccine, AstraZeneca has kicked off a new service delivering its FluMist directly to consumers.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "3bf7N8mT",
      "url": "https://www.fiercepharma.com/pharma/battle-obesity-drug-heavyweights",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:22pm",
      "snippet": "In this episode of \"The Top Line,\" we unpack how Novo Nordisk and Eli Lilly’s latest earnings, pipeline moves and rising competition are reshaping the high-stakes race in obesity drugs.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "wLSsQrK1",
      "url": "https://www.fiercepharma.com/pharma/precigen-scores-fda-nod-first-ever-treatment-hpv-related-disorder",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 15, 2025 8:21am",
      "snippet": "The FDA has approved a treatment for recurrent respiratory papillomatosis for the first time. The agency has signed off on Precigen’s Papzimeos, a non-replicating adenoviral vector-based immunotherapy, which can eliminate the need for repeated surgical interventions to remove ben",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "dUPAgd5K",
      "url": "https://www.fiercepharma.com/pharma/padcev-new-breakthrough-alzheimers-drug-grim-fate-fosun-645m-deal",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 6:00pm",
      "snippet": "The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. Fosun Pharma is out-licensing its DPP1 inhibitor for up to $645 million. And more.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "OwVw8ghh",
      "url": "https://www.fiercepharma.com/pharma/hhs-revives-90s-task-force-designed-improve-safety-childhood-vaccines",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:29pm",
      "snippet": "The Department of Health and Human Services is relaunching a task force focused on the safety of childhood vaccines. The federal panel will be chaired by National Institutes of Health Director Jay Bhattacharya, M.D., Ph.D.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "GXM1SFZj",
      "url": "https://www.fiercepharma.com/pharma/eli-lilly-endorses-trumps-goal-aligning-international-drug-prices",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 1:22pm",
      "snippet": "Eli Lilly said it has \"intensified efforts to&nbsp;align prices across developed countries\" in recent months. Besides a new U.K. price hike, Lilly said it may make other \"necessary pricing adjustments\" by Sept. 1.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HzWX-jRW",
      "url": "https://www.fiercepharma.com/marketing/enhertu-keytruda-promos-put-az-merck-front-oncology-hcp-marketing-pack-report",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 11:53am",
      "snippet": "An analysis of how cancer drugmakers interact with oncologists found, perhaps unsurprisingly, that those interactions are dominated by therapies boasting a broad reach and targeting the most common cancers.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yZdh_svo",
      "url": "https://www.fiercebiotech.com/medtech/medtronic-expands-board-chase-ma-efficiencies-activist-investor-takes-stake",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 10:27am",
      "snippet": "The company’s newest stakeholder, Elliott Investment Management, said it has become one of Medtronic's largest investors.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yKjMYHsv",
      "url": "https://www.fiercebiotech.com/biotech/ptc-therapeutics-friedreichs-ataxia-hopes-derailed-crl-fda",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 10:32am",
      "snippet": "Despite missing its primary endpoint in a phase 3 study, PTC had held out hope that another endpoint would help its candidate pass muster with the FDA.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "QLaQ7spq",
      "url": "https://www.fiercebiotech.com/biotech/fda-pushes-back-pdufa-date-regenxbios-hunter-syndrome-gene-therapy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 9:08am",
      "snippet": "Delays from the Food and Drug Administration continue to pile up, with Maryland-based Regenxbio the latest to report the review of one of its assets has been extended.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WFWD2bcx",
      "url": "https://www.fiercebiotech.com/biotech/viking-hits-stormy-seas-phase-2-oral-obesity-data-sink-stock",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 9:21am",
      "snippet": "Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But with 38% of patients discontinuing treatment at the most effective dose, investors sent the stock down 37% in premarket trading.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "OyuFzzpk",
      "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2025",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Dec 23, 2024 11:52am",
      "snippet": "As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "I7ZDh7pR",
      "url": "https://www.fiercebiotech.com/biotech/opthea-still-reeling-eye-disease-flops-ramps-layoffs-85-and-loses-ceo",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 5:32am",
      "snippet": "Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company isn’t quite ready to give up.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.39999999999999997,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HwpUXT7x",
      "url": "https://www.fiercebiotech.com/biotech/chinas-remegen-sells-asia-rights-vegffgf-eye-drug-180m-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 6:17am",
      "snippet": "China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 million Chinese yuan ($34.8 million) upfront.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "kiGyxqgi",
      "url": "https://www.fiercebiotech.com/biotech/csl-lay-15-workforce-cut-rd-costs-and-spin-out-vaccine-unit",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 19, 2025 4:33am",
      "snippet": "CSL is laying off up to 15% of its workforce as the company looks to cut R&amp;D costs and spin out its vaccine subsidiary.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zptqQjZQ",
      "url": "https://www.fiercebiotech.com/biotech/shankar-ramaswamys-gene-therapy-biotech-raises-313m",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 4:29pm",
      "snippet": "Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "6XpAxd6e",
      "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Dec 23, 2024 12:22pm",
      "snippet": "The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5sM6xtXU",
      "url": "https://www.fiercebiotech.com/biotech/genentechs-summer-struggle-continues-scrapped-2b-cell-therapy-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 2:14pm",
      "snippet": "Genentech’s summer of downsizing and cost-cutting continued this morning, with the Roche subsidiary announcing the termination of a cell therapy deal worth as much as $2 billion. The pact with Adaptive Biotechnologies, originally launched in January 2019, was meant to see Genente",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "SbKGbpgW",
      "url": "https://www.fiercebiotech.com/cro/private-equity-firm-acquires-clinical-trial-site-network-headlands-research",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 12:05pm",
      "snippet": "After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself. Headlands has been scooped up by private equity firm THL Partners, which entered an agreement to buy the clinical trial company from founding firm KKR.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CTGGV_09",
      "url": "https://www.fiercebiotech.com/biotech/stealth-bio-submits-fda-application-rare-disease-candidate-third-time-0",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 11:17am",
      "snippet": "After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational treatment designed to treat an ultra-rare genetic disease.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "0pbvvwzF",
      "url": "https://www.fiercebiotech.com/biotech/neurizon-becomes-second-biotech-hit-fda-delay-als-candidate",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 10:48am",
      "snippet": "Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. Neurizon, an Australian biotech focusing on neurodegenerative diseases, will now have to wait until Oct. 3 before receiving a response on whether its amyotr",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pSDNg4Gh",
      "url": "https://www.fiercebiotech.com/medtech/baxters-novum-iq-corrections-grow-scope-include-syringe-pumps",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 11:05am",
      "snippet": "Last month, Baxter and the FDA highlighted a problem with the Novum IQ large-volume pump, tied to 79 serious injuries and two deaths. Now, separate software issues are affecting both the large-volume system as well as its syringe-based pump.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "YPpsaygg",
      "url": "https://www.fiercebiotech.com/biotech/merck-kgaa-swoops-2b-neurological-disease-pact-skyhawk",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 9:35am",
      "snippet": "Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "03qKxhSU",
      "url": "https://www.fiercebiotech.com/biotech/reunions-psychedelic-prodrug-reduces-post-partum-depression-phase-2-study",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 5:59am",
      "snippet": "Reunion Neuroscience’s psychedelic has reduced the symptoms of postpregnancy depression in a phase 2 study, setting up the biotech to enter late-stage trials next year.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "w7aObQFo",
      "url": "https://www.fiercebiotech.com/biotech/pfizers-scd-drug-fails-phase-3-study-latest-blow-global-blood-therapeutics-legacy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 18, 2025 4:48am",
      "snippet": "Pfizer’s sickle cell disease drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "DDOWAyOM",
      "url": "https://www.fiercebiotech.com/pharma/fiercest-women-life-sciences-2025-nominations-open-now",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 15, 2025 12:13pm",
      "snippet": "Every year, Fierce celebrates women making a powerful impact across biopharma and medtech. It’s time once again to make your suggestions for this year’s honorees.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "oyTp2lSp",
      "url": "https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 2:53pm",
      "snippet": "Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide).",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "pqYzpBsa",
      "url": "https://www.fiercepharma.com/pharma/outlook-therapeutics-outlook-dims-fda-snubs-reformulated-avastin-eye-disease-again",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 10:31am",
      "snippet": "For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "lCHpJPkB",
      "url": "https://www.fiercepharma.com/marketing/maze-therapeutics-referred-federal-marketing-regulators-over-challenge-brought-vertex",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 10:50am",
      "snippet": "After Maze Therapeutics opted not to participate in the National Advertising Division’s self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex Pharmaceuticals is being escalated to federal authorities.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "JDYzTXmg",
      "url": "https://www.fiercepharma.com/pharma/roche-begins-construction-7000m-obesity-drug-manufacturing-facility-north-carolina",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 7:32am",
      "snippet": "Roche’s U.S. subsidiary Genentech broke ground Monday on a $700 million plant tabbed for operation in 2029. The fill-finish plant, which will help produce obesity drugs, is part of Roche’s plan to invest $50 billion in the U.S. over the next five years.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "g2ituYev",
      "url": "https://www.fiercepharma.com/pharma/pfizer-biontech-pick-fda-approval-years-updated-mrna-covid-shot",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 27, 2025 1:15pm",
      "snippet": "Amid uncertainty over how the Trump administration would approach mRNA vaccines for the upcoming COVID-19 season, the FDA has approved updated shots from Pfizer and Moderna. But rather than granting the broad endorsements the vaccines previously enjoyed, the administration is res",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "osC32Q-Q",
      "url": "https://www.fiercepharma.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 27, 2025 2:03pm",
      "snippet": "Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the oncology company’s Pennsylvania site wind down and 130 employees laid off, a company spokesperson confirmed to Fierce Biotech.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "JNIwGL1l",
      "url": "https://www.fiercepharma.com/pharma/remegen-vor-bio-score-again-telitacicept-time-igan",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 27, 2025 10:28am",
      "snippet": "China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after revealing the success of a phase 3 trial of telitacicept in&nbsp;Sjögren’s disease, the companies have reported another late-stage win",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "XofKqA8j",
      "url": "https://www.fiercepharma.com/marketing/clevelanddx-reboots-psa-psa-campaign-drive-prostate-cancer-screening",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 26, 2025 5:25pm",
      "snippet": "For the third year in a row, Cleveland Diagnostics is commemorating September’s Prostate Cancer Awareness Month with its “A PSA on PSA” campaign that serves as a public service announcement about prostate-specific antigen testing.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1CA42Vv2",
      "url": "https://www.fiercepharma.com/pharma/excelltheras-novel-blood-cancer-stem-cell-therapy-zemcelpro-earns-eu-nod",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 21, 2025 11:59am",
      "snippet": "The therapy offers a more accessible option to patients with hematological malignancies (blood cancers) who don't have access to suitable donor cells for traditional stem cell transplants.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "48X_szKG",
      "url": "https://www.fiercepharma.com/health-tech/eversana-waltz-health-merge-and-form-combined-pharmaceutical-pricing-platform",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 26, 2025 1:35pm",
      "snippet": "The deal will bring together Waltz's proprietary drug marketplaces and direct-to-payer model with Eversana's global pharmaceutical commercialization platform.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "l85IuwPi",
      "url": "https://www.fiercepharma.com/biotech/8-months-after-bergers-departure-sanofi-snags-biomarin-leader-take-cmo-role",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 26, 2025 11:10am",
      "snippet": "Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected a successor.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "esGxOHrr",
      "url": "https://www.fiercebiotech.com/biotech/fda-considers-non-invasive-liver-endpoint-trials-sending-mash-biotechs-stock",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 10:45am",
      "snippet": "The FDA has begun considering a noninvasive liver measurement as a surrogate endpoint for certain MASH patients, a move that could speed up drug development in the space.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "tlp3gYEs",
      "url": "https://www.fiercebiotech.com/medtech/fda-flags-issues-review-telixs-pet-diagnostic-agent-kidney-cancer",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 10:57am",
      "snippet": "The FDA has asked Telix for more information about the manufacturing of its novel PET agent for clear-cell renal cell carcinoma.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "W5ACIv4n",
      "url": "https://www.fiercebiotech.com/biotech/flagship-pioneering-taps-iqvia-biotech-support-company-fleet",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 10:54am",
      "snippet": "Flagship Pioneering is boosting the clinical research capabilities of its biotech fleet with a new IQVIA collaboration. The CRO giant will provide Flagship’s companies with its artificial intelligence and clinical trial technologies to enhance their drug development and early com",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "MeqS5Oor",
      "url": "https://www.fiercebiotech.com/biotech/novo-nordisk-seeks-obesity-refresh-550m-replicate-research-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 5:20pm",
      "snippet": "As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration with Replicate Bioscience potentially worth $550 m",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "TXA6rW8g",
      "url": "https://www.fiercebiotech.com/biotech/prothenas-alzheimers-trial-hit-aria-showstopper-resulting-non-competitive-profile",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 6:17am",
      "snippet": "A phase 1 study has linked Prothena’s anti-amyloid beta antibody to a higher rate of brain swelling than rival approved drugs, hindering the biotech’s positioning in early symptomatic Alzheimer’s disease.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "G3h21_0z",
      "url": "https://www.fiercebiotech.com/biotech/exelixis-lay-130-employees-shut-down-pennsylvania-site-post-pandemic-downsizing",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 2:03pm",
      "snippet": "Mere months after its cancer blockbuster hopeful topped Bayer’s Stivarga in a phase 3 trial, Exelixis is conducting a reorganization that will see the oncology company’s Pennsylvania site wind down and 130 employees laid off, a company spokesperson confirmed to Fierce Biotech.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "fNCrS30D",
      "url": "https://www.fiercebiotech.com/research/new-foundation-microsoft-co-founder-unveils-inaugural-research-grants-plans-500m-giving",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 11:36am",
      "snippet": "A new foundation from the estate of late Microsoft co-founder Paul Allen has launched with a set of four research grant recipients and plans to give $500 million over the next four years to support progress in bioscience, environmental science and AI development.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "B6LYrCkU",
      "url": "https://www.fiercebiotech.com/biotech/nykode-sticks-its-neck-out-betting-future-phase-2-cancer-trial-after-losing-genentech-pact",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 7:38am",
      "snippet": "Nykode Therapeutics has designed a two-year plan to turn its fortunes around. Having lost a deal with Genentech—and with the future of a Regeneron pact uncertain—the Norwegian biotech is focusing on delivering phase 2 data in head and neck cancer before its cash runway runs out.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "kXkuKpEW",
      "url": "https://www.fiercebiotech.com/biotech/wugen-woos-vcs-landing-115m-bring-fratricide-proof-car-t-cell-therapy-market",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 27, 2025 8:53am",
      "snippet": "Wugen has raised $115 million, tapping a Fidelity-led syndicate to fund its pursuit of FDA approval for the first off-the-shelf CAR-T for T-cell malignancies. A pivotal trial is underway, putting the company on track to seek approval in 2027.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "C2nXfUAU",
      "url": "https://www.fiercebiotech.com/cro/chinese-cro-chempartner-announces-new-boston-research-facility",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 2:29pm",
      "snippet": "Chinese contract research and manufacturing outfit ChemPartner is building out its U.S. footprint in the heart of the bustling Boston biotech scene. The company’s new Boston Center of Excellence is set to open in Watertown, Massachusetts, on Sept. 10, ChemPartner announced in an ",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1YIn8XvZ",
      "url": "https://www.fiercebiotech.com/biotech/forbion-orbimed-backed-sitala-seals-670m-deal-fosun-immune-disease-drug",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 2:25pm",
      "snippet": "Right on the heels of a similar deal, Fosun Pharma has outlicensed a second inflammatory disease candidate to a Western biotech startup.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "qmBHbpSz",
      "url": "https://www.fiercebiotech.com/biotech/8-months-after-bergers-departure-sanofi-snags-biomarin-leader-take-cmo-role",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 11:10am",
      "snippet": "Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected a successor.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zwsF8YJH",
      "url": "https://www.fiercebiotech.com/research/lineage-cell-therapeutics-tunes-hearing-loss-transplant-12m-research-pact",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 10:47am",
      "snippet": "Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for auditory neurons. William Demant Invest, the largest shareholder of Danish hearing aid manufacturer Demant, has earmarked up to $12 million to support preclinical",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "jEAQFrIQ",
      "url": "https://www.fiercebiotech.com/biotech/regeneron-reports-phase-3-win-advancing-push-muscle-myasthenia-gravis",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 9:03am",
      "snippet": "Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "oz0P6P2y",
      "url": "https://www.fiercebiotech.com/biotech/novartis-pens-30m-upfront-bioarctic-pact-pair-seek-out-neurodegeneration-meds",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 26, 2025 2:52am",
      "snippet": "Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new drug in the neurodegeneration space.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "RgNFjlYK",
      "url": "https://www.fiercepharma.com/pharma/pd-1xvegf-first-os-win-fosun-sitala-670m-deal-hutchmed-acting-ceo",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 28, 2025 3:36pm",
      "snippet": "Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma out-licensed another immune disease candidate. Hutchmed's CEO took medical leave. And more.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WAC_HO5x",
      "url": "https://www.fiercepharma.com/marketing/lilly-links-jd-health-dtc-obesity-diabetes-drug-sales-china",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:02am",
      "snippet": "Amid a growing push for more direct-to-consumer access to some of the world’s most popular drugs, Eli Lilly has inked a deal with China’s JD Health to sell its obesity, Type 2 diabetes and alopecia areata meds in the country through a digital health platform.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ozu9grr-",
      "url": "https://www.fiercepharma.com/pharma/university-michigan-sues-astrazeneca-targeting-influenza-master-strains-used-flumist",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 9:40am",
      "snippet": "The University of Michigan is suing AstraZeneca over claims that the British drugmaker continues to market and sell FluMist despite not renewing a key contract with the school that was crucial to the vaccine's development.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "R2Cu3zua",
      "url": "https://www.fiercebiotech.com/biotech/fosun-rises-again-inking-3rd-inflammatory-disease-deal-3-weeks",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 29, 2025 9:33am",
      "snippet": "Fosun Pharma has penned its third inflammatory disease pact in three weeks, plucking up China rights to a clinical-stage treatment from Accro Bioscience.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "AW3x9TmF",
      "url": "https://www.fiercebiotech.com/biotech/beone-hits-primary-endpoint-setting-stage-filings-take-blood-cancer-mantle",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 29, 2025 9:25am",
      "snippet": "A phase 1/2 trial of BeOne Medicines’ sonrotoclax has hit its primary endpoint, furthering the biotech’s plans to launch the first BCL2 inhibitor for use in mantle cell lymphoma.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "bAHaZ3S6",
      "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-sanofi-snags-cmo-biomarin",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 28, 2025 4:58pm",
      "snippet": "Eight months after Sanofi’s former chief medical officer, Dietmar Berger, M.D., departed, the French drugmaker has selected Marcia Kayath, M.D., Ph.D., to fill the role. Kayath will start in her new role at Sanofi Sept. 2 and will report to Sanofi’s R&amp;D head, Houman Ashrafian",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "FJlm9QIp",
      "url": "https://www.fiercepharma.com/pharma/sanofi-rilzabrutinib-fda-approval-immune-thrombocytopenia-itp",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 14, 2025 3:32pm",
      "snippet": "While Sanofi originally had its eye on tolebrutinib when it purchased its partner Principia Biopharma for $3.7 billion, another of the biotech’s BTK inhibitors has made it across the FDA finish line first.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "Jl-gNoaw",
      "url": "https://www.fiercepharma.com/pharma/eisai-secures-highly-anticipated-fda-green-light-leqembi-iqlik-autoinjector-teeing-home",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 12:15pm",
      "snippet": "The FDA has&nbsp;approved a once-weekly subcutaneous maintenance dose of Leqembi in an autoinjector, dubbed Leqembi IQLIK, which Eisai has hailed as a key milestone in its quest to grow the reach of the Alzheimer's disease medicine. With a green light in hand, Eisai will also pro",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "ko-HReXU",
      "url": "https://www.fiercepharma.com/biotech/zydus-phase-3-liver-disease-win-tees-filing-challenge-gilead-and-ipsen",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:50am",
      "snippet": "Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "-4tYW29z",
      "url": "https://www.fiercepharma.com/pharma/after-trial-failure-jj-halts-imaavy-combo-agent-rheumatoid-arthritis",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:19am",
      "snippet": "Flying high after an FDA approval four months ago to treat generalized myasthenia gravis, Johnson &amp; Johnson’s much-touted Imaavy has taken a hit, coming up short as part of a combination therapy in a rheumatoid arthritis trial.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "aNNtHuiB",
      "url": "https://www.fiercepharma.com/pharma/pfizer-discontinue-low-dose-attr-drug-vyndaqel-us-ahead-2028-patent-loss",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Aug 29, 2025 10:02am",
      "snippet": "Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM).",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "I2FNlw_a",
      "url": "https://www.fiercebiotech.com/biotech/zydus-phase-3-liver-disease-win-tees-filing-challenge-gilead-and-ipsen",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Aug 29, 2025 10:50am",
      "snippet": "Zydus Therapeutics has racked up a phase 2b/3 win in primary biliary cholangitis, clearing the path to a filing to establish the company as a challenger to Gilead, Intercept Pharmaceuticals and Ipsen.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "6Rdtmhxp",
      "url": "https://www.fiercepharma.com/pharma/intercept-pulls-liver-disease-drug-ocaliva-us-after-regulatory-struggles-fda-orders-clinical",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 10:33am",
      "snippet": "The FDA has officially put its foot down on Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, requesting that the company pull the med from the market and putting all of its related trials on a clinical hold.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "PS74tBuG",
      "url": "https://www.fiercepharma.com/pharma/despite-being-designed-seniors-mercks-pneumococcal-shot-excels-trial-children",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 10:33am",
      "snippet": "Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed largely as the first shot designed for seniors—Merck’s Capvaxive has data supporting its potential in children and adolescents from a phase 3 trial.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "YWuDGOBw",
      "url": "https://www.fiercepharma.com/biotech/fibrogen-pays-sec-12m-over-allegations-former-exec-reverse-engineered-roxadustat-data",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 9:40am",
      "snippet": "FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission to address allegations that its former chief medical officer manipulated data for the anemia drug roxadustat.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "BKQVSNU6",
      "url": "https://www.fiercepharma.com/manufacturing/suns-gujarat-facility-put-fda-import-alert-ongoing-contamination-issues",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 9:00am",
      "snippet": "Ongoing issues at Sun Pharma’s production facility in Gujarat, India, have resulted in the FDA putting the facility on import alert status.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "CW7W5f8_",
      "url": "https://www.fiercepharma.com/marketing/sanofi-gilead-acadia-win-big-2025-fierce-pharma-marketing-awards",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 7:29am",
      "snippet": "This year’s Fierce Pharma Marketing Awards gala, which took place in Philadelphia on Wednesday night, saw several major drugmakers take home trophies.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "aojJgiNI",
      "url": "https://www.fiercepharma.com/manufacturing/api-maker-hikal-slammed-warning-letter-after-repeated-complaints-contamination",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 8:10am",
      "snippet": "India’s Hikal Limited has been hit with a warning letter from the FDA that chided the API drugmaker for failing to uncover the cause of almost two dozen complaints of metal contamination in its products.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "CwfS4Kfn",
      "url": "https://www.fiercepharma.com/biotech/merck-executes-its-own-brexit-moving-all-rd-operations-out-uk",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 3:21pm",
      "snippet": "Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&amp;D center and future U.K. headquarters in London, Merck is not only bailing on the project but is discontinuing all of its research operations in Britain, citing an unwelcoming",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "4jGnS75L",
      "url": "https://www.fiercepharma.com/pharma/first-pd-1xvegfs-sake-summit-must-submit-big-pharma-stat",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 1:57pm",
      "snippet": "The highly debatable HARMONi data, along with the trial design flaws and the unfortunate execution they reflect, plus a rapidly evolving competitive landscape, all point to one conclusion: Summit must partner with a Big Pharma company as soon as possible.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "vuHEAOhr",
      "url": "https://www.fiercepharma.com/marketing/pharmas-looking-break-through-clutter-and-reach-patients-relatability-key",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 1:41pm",
      "snippet": "To really move the needle and reach consumers, it’s critical that ad spots come with a clear sense of authenticity and relatability in addition to the glitz and glam of Hollywood fame, experts said during a panel at Fierce Pharma Week.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "EuREO2D9",
      "url": "https://www.fiercepharma.com/marketing/landmines-everywhere-how-pharma-communications-keep-under-political-spotlight",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 12:11pm",
      "snippet": "Industry media leads joined a Fierce Pharma Week panel to discuss their shifting communication strategies amid an unfamiliar and turbulent political and policy era.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ZUks3oUB",
      "url": "https://www.fiercepharma.com/marketing/trump-directs-fda-limit-dtc-drug-advertising-legal-challenges-sure-follow",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 11:05am",
      "snippet": "President Donald Trump has delivered another blow in his ongoing battle with the pharma industry, signing a memorandum on Tuesday that directs the FDA to rein in direct-to-consumer (DTC) drug advertising.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "jnCHOEaD",
      "url": "https://www.fiercepharma.com/pharma/johnson-johnsons-practice-changing-bladder-cancer-drug-device-combo-inlexzo-crosses-fda",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 9:49am",
      "snippet": "The drug-releasing system combo is approved to treat patients with bladder cancer who face removal of the organ after not responding to the standard-of-care Bacillus Calmette-Guérin treatment in the first-line setting.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "lRNC0WCW",
      "url": "https://www.fiercepharma.com/biotech/trump-admin-mulls-severe-restrictions-us-pharmas-securing-chinese-meds-nyt",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 8:43am",
      "snippet": "The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "W2TtPscu",
      "url": "https://www.fiercepharma.com/pharma/novo-nordisk-lay-9000-workers-new-ceo-aims-save-13b-year-late-2026",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 8:39am",
      "snippet": "In a bid to save around 8 billion Danish kroner ($1.3 billion) annually by the end of 2026, Novo will lay off roughly 9,000 employees across its global workforce of 78,400. Some 5,000 job cuts will occur in Novo’s home country of Denmark, the company said.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "eJ97Wf1s",
      "url": "https://www.fiercepharma.com/pharma/takeda-faces-another-pay-delay-antitrust-lawsuit-one-cvs-over-heartburn-drug-dexilant",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 10, 2025 7:07am",
      "snippet": "Six months after Walgreens and three other retailers&nbsp;brought an antitrust lawsuit against Takeda and TWi Pharmaceuticals over an alleged “pay-for-delay” scheme, CVS has filed a similar antitrust complaint against the same companies.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QnqxHiZU",
      "url": "https://www.fiercepharma.com/marketing/rising-stars-how-arc-bios-kareem-clark-uses-his-neuroscience-background-help-clients",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 9, 2025 4:12pm",
      "snippet": "In a Q&amp;A for Fierce Pharma Marketing’s “Rising Stars” series, Kareem Clark explained how the pandemic led him to understand the importance of communicating scientific advances, and why he thinks agencies need to work harder to use the talents of all their employees.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ZZ2RJRZn",
      "url": "https://www.fiercebiotech.com/biotech/arrowhead-battles-ionis-over-patent-dispute-tied-rnai-candidate-could-rival-tryngolza",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 11:01am",
      "snippet": "Arrowhead Pharmaceuticals has launched legal action against Ionis Pharmaceuticals, aiming to neutralize Ionis' claim that Arrowhead's potential rival to Tryngolza breaches a patent.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Ey44iJcy",
      "url": "https://www.fiercebiotech.com/biotech/fibrogen-pays-sec-12m-over-allegations-former-exec-reverse-engineered-roxadustat-data",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 9:40am",
      "snippet": "FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission to address allegations that its former chief medical officer manipulated data for the anemia drug roxadustat.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "8uaQUtI3",
      "url": "https://www.fiercebiotech.com/biotech/capsida-pauses-phase-1-gene-therapy-trial-after-child-dies",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 7:08am",
      "snippet": "Capsida Biotherapeutics has paused a gene therapy clinical trial after the first patient died. The biotech, which began the phase 1/2 study in July, took the action to give it time to determine the root cause of the death.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "43mqwSV2",
      "url": "https://www.fiercebiotech.com/biotech/lb-pharmaceuticals-upsizes-ipo-285m-first-biotech-listing-months",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 4:11am",
      "snippet": "LB Pharmaceuticals’ decision to break cover and go public seems to have paid off, with the company bumping up the number of shares on offer for its Nasdaq listing this morning.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "YCCkDSuz",
      "url": "https://www.fiercebiotech.com/biotech/uk-life-sci-investments-lag-abpi-spotlights-countrys-competitive-pitfalls",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 3:08pm",
      "snippet": "One week after warning that the United Kingdom is undervaluing life sciences manufacturing investments, trade organization the Association of the British Pharmaceutical Industry has issued another call to action for policymakers and the local biopharma scene.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "2ESo6UBt",
      "url": "https://www.fiercebiotech.com/biotech/merck-executes-its-own-brexit-moving-all-rd-operations-out-uk",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 3:21pm",
      "snippet": "Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&amp;D center and future U.K. headquarters in London, Merck is not only bailing on the project but is discontinuing all of its research operations in Britain, citing an unwelcoming",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "LFe9pGRA",
      "url": "https://www.fiercebiotech.com/pharma/first-pd-1xvegfs-sake-summit-must-submit-big-pharma-stat",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 1:57pm",
      "snippet": "The highly debatable HARMONi data, along with the trial design flaws and the unfortunate execution they reflect, plus a rapidly evolving competitive landscape, all point to one conclusion: Summit must partner with a Big Pharma company as soon as possible.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QzNef0p-",
      "url": "https://www.fiercebiotech.com/cro/iqvia-unveils-ai-suite-managing-clinical-trial-finances",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 2:29pm",
      "snippet": "IQVIA is unveiling a new suite of tools designed to manage all the financial components of clinical trials.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Qho9iULj",
      "url": "https://www.fiercebiotech.com/cro/phasev-launches-trial-optimizing-software-cro-bioforums-offerings",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 11:45am",
      "snippet": "Clinical software developer PhaseV is teaming up with another global CRO, unveiling a plan to infuse its trial design platform into Bioforum’s services.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "b62EnRZh",
      "url": "https://www.fiercebiotech.com/biotech/mei-pharma-leaves-biotech-woes-behind-rebrand-crypto-company",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 10:01am",
      "snippet": "From now on, MEI Pharma—previously best known for its clinical-stage leukemia drug—will be called Lite Strategy.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "mes66xVy",
      "url": "https://www.fiercebiotech.com/biotech/pmv-plots-ovarian-cancer-filing-after-seeing-midphase-data",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 9:22am",
      "snippet": "PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval in the first quarter of 2027.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "QRvcMPL-",
      "url": "https://www.fiercebiotech.com/biotech/trump-admin-mulls-severe-restrictions-us-pharmas-securing-chinese-meds-nyt",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 8:43am",
      "snippet": "The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Hjzte--p",
      "url": "https://www.fiercebiotech.com/pharma/novo-nordisk-lay-9000-workers-new-ceo-aims-save-13b-year-late-2026",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 10, 2025 8:39am",
      "snippet": "In a bid to save around 8 billion Danish kroner ($1.3 billion) annually by the end of 2026, Novo will lay off roughly 9,000 employees across its global workforce of 78,400. Some 5,000 job cuts will occur in Novo’s home country of Denmark, the company said.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QK_HsBNo",
      "url": "https://www.fiercebiotech.com/biotech/odyssey-therapeutics-heralds-213m-series-d-strengthen-clinical-portfolio",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 9, 2025 5:51pm",
      "snippet": "Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D round after abandoning plans to go public this summer.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "M-Nf3lsz",
      "url": "https://www.fiercebiotech.com/biotech/capricor-shares-response-cell-therapy-denial-after-fda-publicly-releases-rejection-letter",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 9, 2025 11:13am",
      "snippet": "Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of complete response letters released Sept. 4.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "44DoGSaH",
      "url": "https://www.fiercepharma.com/marketing/keep-doing-what-youre-doing-marketing-policy-experts-talk-defense-against-threats-dtc",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 3:18pm",
      "snippet": "In a Fierce Pharma Week panel, experts including Coalition for Healthcare Communication Director James Potter discussed why President Donald Trump's threats to drug advertising may be more bark than bite.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "MRGaZq_X",
      "url": "https://www.fiercepharma.com/pharma/trump-officials-eye-connection-between-covid-shots-infant-deaths-ahead-acip-meeting-wapo",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 2:15pm",
      "snippet": "As Robert F. Kennedy Jr.’s revamped CDC vaccine advisory panel gears up to meet next week, U.S. health officials are reportedly planning to connect the deaths of 25 children to the use of COVID shots.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "nY5BmDRL",
      "url": "https://www.fiercepharma.com/marketing/chronic-disease-treatment-ads-have-sparked-action-two-thirds-patients-survey",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 12:20pm",
      "snippet": "Amid the Trump administration’s call for a crackdown on direct-to-consumer pharmaceutical advertising, a new survey shows that many people with chronic conditions have been inspired by such ads to take some sort of action for their health.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Sa5gAbdA",
      "url": "https://www.fiercepharma.com/marketing/doctor-mike-calls-healthcare-pharma-leaders-lean-social-media-rebuild-trust",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 4:54pm",
      "snippet": "In the current climate, there is an urgent need for credible voices online, Doctor Mike noted in a discussion at Fierce Pharma Week. But the key is to create content that is transparent, authentic, educational and valuable.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Aycj6XCj",
      "url": "https://www.fiercepharma.com/pharma/gilead-prevails-whistleblower-lawsuit-over-alleged-hepatitis-c-prescription-kickbacks",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 12, 2025 11:06am",
      "snippet": "A federal judge granted Gilead summary judgment in a lawsuit that claimed the company used sham speaker events to induce doctors to write hepatitis C drug prescriptions.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pjKY5niR",
      "url": "https://www.fiercepharma.com/pharma/trump-mulls-crackdown-china-deals-daiichi-mercks-adc-win-suns-import-ban",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 11, 2025 3:10pm",
      "snippet": "The Trump administration is reportedly weighing an executive order to limit drug licensing deals with China biotechs. Daiichi Sankyo and Merck are angling for an FDA accelerated approval for their B7-H3 ADC. Sun Pharma's beleaguered Halol plant has been slapped with an FDA import",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "vVwOyY0U",
      "url": "https://www.fiercebiotech.com/biotech/astrazeneca-pauses-271m-expansion-uk-latest-big-pharma-buck-britain",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 2:20pm",
      "snippet": "AstraZeneca has paused a 200 million pound sterling (about $271 million) investment in its Cambridge, England, research site, the latest Big Pharma to pull back from the U.K. this week, a company spokesperson has confirmed to Fierce Biotech.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "wAijvgNa",
      "url": "https://www.fiercebiotech.com/medtech/neurescues-resuscitation-device-nets-eu-approval-non-shockable-cardiac-arrests",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 1:08pm",
      "snippet": "Neurescue has been working for over a decade to develop an easy-to-use system capable of directing oxygenated blood to the heart and brain when it’s needed most.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "EB7EqfpW",
      "url": "https://www.fiercebiotech.com/biotech/eli-lilly-reconsiders-uk-biotech-incubator-pauses-buildout-report",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 11:42am",
      "snippet": "Eli Lilly is reconsidering plans for its U.K. biotech-focused Gateway Labs amid concerns about the industry’s outlook in the country and low government spend on drug development, according to reports from several outlets.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "_sM8w7qG",
      "url": "https://www.fiercebiotech.com/biotech/galimedix-seeks-phase-2-funding-after-oral-alzheimers-candidate-clears-safety-test",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 12, 2025 11:00am",
      "snippet": "Maryland-based biotech Galimedix Therapeutics is ready to take a big swing on its oral Alzheimer’s disease candidate after the small molecule caused no serious adverse events and successfully crossed the blood-brain barrier in a phase 1 trial.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "3XTOjnTu",
      "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-takeda-taps-longtime-lilly-exec-us-head",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 11, 2025 4:55pm",
      "snippet": "With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona Pacheco. Pacheco is set to leave behind her role as Eli Lilly’s VP of U.S. cardiometabolic health, the most recent title she’s held along her 20-year tenure ",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "u2UqDshJ",
      "url": "https://www.fiercepharma.com/pharma/fda-greenlights-stealth-bios-injection-1st-treatment-barth-syndrome",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 19, 2025 5:44pm",
      "snippet": "After a tumultuous journey filled with delays and rejection, the FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy for the condition.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "etfkcgYm",
      "url": "https://www.fiercepharma.com/pharma/kennedys-acip-narrowly-avoids-vote-require-covid-19-vaccine-prescriptions",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 19, 2025 5:01pm",
      "snippet": "In the second and final day of the CDC’s Advisory Committee on Immunization Practices September meeting, members of the panel scrapped one vote, reversed another and stopped just short of endorsing a third that had the potential to significantly impede COVID-19 vaccine access for",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "0B2uH20o",
      "url": "https://www.fiercepharma.com/pharma/merck-scores-fda-approval-subcutaneous-keytruda",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 19, 2025 4:35pm",
      "snippet": "The FDA has approved Merck &amp; Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "id0izit6",
      "url": "https://www.fiercepharma.com/pharma/cdc-strongly-backs-gileads-hiv-prep-yeztugo-access-barriers-remain-advocacy-groups-say",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 19, 2025 10:55am",
      "snippet": "The CDC's recommendation for Gilead's twice-yearly Yeztugo as an HIV PrEP option was hailed by HIV advocacy groups but stirred up pressure for CVS Health to include the drug on its formularies.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "nho2ESn5",
      "url": "https://www.fiercepharma.com/pharma/novos-once-weekly-combo-drug-type-2-diabetes-scores-eu-endorsement",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 19, 2025 10:46am",
      "snippet": "Europe's Committee for Medicinal Products for Human Use (CHMP) has recommended several drugs for approval, including Novo Nordisk's once-weekly diabetes drug Kyinsu and Bayer's menopause treatment Lynkuet.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "by9MdmDw",
      "url": "https://www.fiercepharma.com/marketing/rebuilding-trust-pharma-age-misinformation",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 19, 2025 9:56am",
      "snippet": "Freda Lewis-Hall, M.D., former Pfizer chief medical officer, joins \"The Top Line\" to discuss rebuilding patient trust, listening before messaging and what it means to put a human face on pharma.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.5,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "zvG08pnn",
      "url": "https://www.fiercepharma.com/pharma/moderna-alnylam-resolve-patent-litigation-over-covid-19-vaccine-delivery-tech",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 19, 2025 9:13am",
      "snippet": "The lawsuits were part of the large web of COVID-19 vaccine patent infringement cases filed against—and by—the most prominent vaccine makers.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "gR4tCfVB",
      "url": "https://www.fiercepharma.com/pharma/bms-china-asset-sale-2-biotech-debuts-2-potential-deals",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 3:20pm",
      "snippet": "BMS is exiting the first U.S.-China pharmaceutical joint venture. Two biotechs have launched with backing from big venture capital firms and Chinese assets. Roche and Johnson &amp; Johnson are reportedly eyeing an antibody-drug conjugate deal with Henlius. And more.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yBQPWGZW",
      "url": "https://www.fiercepharma.com/pharma/kennedys-revamped-acip-contradicts-itself-confusion-tension-reign-over-mmrv-vaccine-vote",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 6:36pm",
      "snippet": "In a perplexing conclusion to an oftentimes tense meeting of the CDC’s Advisory Committee on Immunization Practices Thursday, the panelists—assembled recently in the aftermath of Robert F. Kennedy Jr.’s purge of the committee—seemed to contradict themselves when it came time to v",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "SnwbNqnC",
      "url": "https://www.fiercepharma.com/manufacturing/expansion-fujifilms-partnership-argenx-will-bring-vyvgart-production-us",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 2:46pm",
      "snippet": "In addition to manufacturing drug substance for argenx’s autoimmune blockbuster Vyvgart at its facility in Hillerød, Denmark, Fujifilm will also make the product at its large-scale complex in Holly Springs, N.C., starting in 2028.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "VeUBu-Zq",
      "url": "https://www.fiercepharma.com/marketing/genentech-names-next-marketing-chief-erica-taylor-takes-new-role-roche",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 1:49pm",
      "snippet": "Nearly three years after originating the role, Erica Taylor, Ph.D., is stepping down as chief marketing officer of Genentech.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5VNpoHTv",
      "url": "https://www.fiercepharma.com/pharma/lillys-mounjaro-primed-expansion-kids-10-17-type-2-diabetes",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 10:47am",
      "snippet": "Over the last six years, three GLP-1 drugs have been approved for children aged 10 and older with Type 2 diabetes. Now this rapidly growing patient population is a step closer to gaining access to Lilly’s dual-action GLP-1/GIP treatment Mounjaro, as its effectiveness in controlli",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "9qLmtsq_",
      "url": "https://www.fiercepharma.com/pharma/novo-nordisk-pads-case-wegovy-pill-oral-obesity-asset-nears-fda-decision",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 9:31am",
      "snippet": "The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity candidate and an Ozempic head-to-head trial win against another stalwart diabetes treatment. In the wake of the results, Novo’s stock was up more than 7% in prem",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "wuWFDgqs",
      "url": "https://www.fiercepharma.com/manufacturing/milliporesigma-debuts-filtration-plant-part-eu440m-investment-ireland",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 7:35am",
      "snippet": "MilliporeSigma, a unit of Germany's Merck KGaA, opened a €150 million ($177 million) filtration products plant in Cork, bolstering the company’s goal to expand global manufacturing operations.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Yc-pCkMI",
      "url": "https://www.fiercepharma.com/marketing/merck-pitches-heart-disease-awareness-campaign-assist-st-louis-cardinals",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 17, 2025 4:58pm",
      "snippet": "Merck is stepping up to the plate to raise awareness of the dangers of high LDL cholesterol and how it can increase the risk of atherosclerotic cardiovascular disease.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "XK6D6q_A",
      "url": "https://www.fiercepharma.com/regulatory/rfk-jr-demanded-vaccine-policy-change-without-evidence-fired-cdc-director-testifies",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 17, 2025 3:26pm",
      "snippet": "Former CDC Director Susan Monarez, Ph.D., told senators the health secretary claimed there was \"no science or evidence\" supporting the current childhood vaccine schedule and that he had the president's backing to impose changes without input from career scientists.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "UFybl952",
      "url": "https://www.fiercepharma.com/pharma/cost-cutting-x4-chops-headcount-50-lays-execs-mission-wrap-xolremdi-expansion-study",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 17, 2025 2:56pm",
      "snippet": "It's the second restructuring this year for X4 Pharmaceuticals as the company moves forward under new leadership and with 50% fewer staff members.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "yDEjbTs-",
      "url": "https://www.fiercepharma.com/marketing/chatgpt-friend-or-foe-pharma-marketers-inizio-evoke-innovation-chief-weighs",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 17, 2025 11:48am",
      "snippet": "As patients and healthcare professionals alike increasingly turn to artificial intelligence tools like OpenAI’s ChatGPT and Google’s Gemini rather than traditional search engines for online research, pharma marketers will need to significantly shift their strategies to ensure the",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "paI1aoCp",
      "url": "https://www.fiercebiotech.com/pharma/fda-greenlights-stealth-bios-injection-1st-treatment-barth-syndrome",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 19, 2025 5:44pm",
      "snippet": "After a tumultuous journey filled with delays and rejection, the FDA has approved Stealth BioTherapeutics’ treatment for the ultrarare disease Barth syndrome, marking the peptide as the first therapy for the condition.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "PpbKqs14",
      "url": "https://www.fiercebiotech.com/pharma/kennedys-acip-narrowly-avoids-vote-require-covid-19-vaccine-prescriptions",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 19, 2025 5:01pm",
      "snippet": "In the second and final day of the CDC’s Advisory Committee on Immunization Practices September meeting, members of the panel scrapped one vote, reversed another and stopped just short of endorsing a third that had the potential to significantly impede COVID-19 vaccine access for",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Sso8LWjK",
      "url": "https://www.fiercebiotech.com/cro/one-third-data-collected-clinical-trials-may-be-unnecessary-study-finds",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 19, 2025 10:35am",
      "snippet": "A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical data collection is translating into an increased burden on patients and trial s",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "f97OhWLx",
      "url": "https://www.fiercebiotech.com/research/japan-biotech-inks-research-pact-efforts-develop-new-rna-meds",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 19, 2025 10:21am",
      "snippet": "Japan biotech xFOREST Therapeutics is teaming up with a drug discovery solutions provider in a research pact that aims to develop new RNA structure-targeted small molecule therapeutics, including mRNA candidates.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Sg7ffS9w",
      "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-catalym-catalyzes-c-suite-shakeup",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 5:13pm",
      "snippet": "The German drug developer has tapped four industry leaders to take up spots in its C-suite, a move that has prompted three other executives to leave the company.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "SlY7Qrhm",
      "url": "https://www.fiercebiotech.com/pharma/kennedys-revamped-acip-contradicts-itself-confusion-tension-reign-over-mmrv-vaccine-vote",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 6:36pm",
      "snippet": "In a perplexing conclusion to an oftentimes tense meeting of the CDC’s Advisory Committee on Immunization Practices Thursday, the panelists—assembled recently in the aftermath of Robert F. Kennedy Jr.’s purge of the committee—seemed to contradict themselves when it came time to v",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "8uwl-DBq",
      "url": "https://www.fiercebiotech.com/biotech/moderna-co-founder-robert-langers-son-launches-new-vc-775m-backing-dad",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 2:47pm",
      "snippet": "Renowned biotech veteran Robert Langer is the executive chair of T.Rx Capital, a VC co-founded by his son Michael Langer and aiming to back \"visionary founders\" at the intersection of technology and biology.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "933w1ORX",
      "url": "https://www.fiercebiotech.com/medtech/stryker-siemens-healthineers-team-develop-stroke-treating-robot",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 11:22am",
      "snippet": "The two companies say the project will leverage Siemens Healthineers’ expertise in imaging and robotics, plus Stryker’s catalog of neurovascular hardware, and bring them together under a single platform.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "jjJHSd-T",
      "url": "https://www.fiercebiotech.com/biotech/carismas-lifeline-dissipates-reverse-merger-plans-fall-through-moderna-cuts-ties",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 10:41am",
      "snippet": "After Carisma Therapeutics laid off 95% of its team earlier this year, a Hail Mary merger proposal with another biotech has fallen through.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "7ATC9loB",
      "url": "https://www.fiercebiotech.com/biotech/biogen-puts-its-back-85m-alcyone-buyout-securing-tech-spinal-drug-delivery",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 10:03am",
      "snippet": "Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pCq2NbuD",
      "url": "https://www.fiercebiotech.com/biotech/pfizer-arvinas-lose-interest-commercializing-protac-inhibitor-leading-layoffs-biotech",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 6:10am",
      "snippet": "Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have decided to wash their hands of the drug.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "m8oBO7UQ",
      "url": "https://www.fiercebiotech.com/biotech/ql-biopharm-links-once-monthly-glp-1-incumbent-rivaling-weight-loss-phase-2",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 18, 2025 4:23am",
      "snippet": "Beijing QL Biopharmaceutical has shared phase 2 data on its once-monthly GLP-1 candidate, providing early evidence that the ultra-long-acting prospect can match the efficacy of weekly products from Eli Lilly and Novo Nordisk.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "fA3IDApv",
      "url": "https://www.fiercebiotech.com/biotech/arsenalbio-lays-50-staff-it-turns-away-early-stage-research",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 17, 2025 4:57pm",
      "snippet": "One of the top fundraisers of 2024 is halving its workforce about a year after bringing in a $325 million series C. Cell therapy biotech Arsenal Biosciences will lay off 50% of its staff as it restructures itself as a clinical-stage company, a spokesperson for the biotech has con",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1C4m7LdS",
      "url": "https://www.fiercebiotech.com/medtech/following-apple-watchs-hypertension-clearance-fda-warns-public-against-using-unauthorized",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 17, 2025 11:02am",
      "snippet": "The FDA is warning the public to avoid using unreviewed devices for checking vital signs due to the risk of unverified and inaccurate readings.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "NRcL6BFW",
      "url": "https://www.fiercebiotech.com/biotech/vc-aditum-launches-cardiovascular-biotech-offers-mabwell-1b-sirna-asset",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 17, 2025 9:54am",
      "snippet": "California VC firm Aditum Bio is at it again, this time partnering up with China-based Mabwell Bioscience to launch a new biotech focused on cardiovascular disease.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WOAl5nSv",
      "url": "https://www.fiercebiotech.com/biotech/jjs-il-23-drug-defeats-reigning-champ-sotyktu-phase-3-psoriasis-trial",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 17, 2025 9:24am",
      "snippet": "After being touted as a potential rival to Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu for months, Johnson &amp; Johnson’s IL-23 drug looks like it has a real shot at taking the crown.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "RpHCsi6z",
      "url": "https://www.fiercepharma.com/sponsored/end-one-way-streets-how-ai-transforming-pharma-email-and-sms",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 18, 2025 3:50pm",
      "snippet": "Perhaps the best way to think of today’s pharma marketing landscape is as a one-way street. Information flows to healthcare professionals (HCPs) through carefully crafted communications, including emails and SMS messages, but physicians often lack an immediate channel to respond.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "t6xFO8eG",
      "url": "https://www.fiercepharma.com/sponsored/marketers-role-earlier-disease-intervention-why-smarter-strategies-matter",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 17, 2025 10:39am",
      "snippet": "Diagnosis and treatment delays cost patient lives. Learn how forward-thinking pharma brands are using smarter marketing to change the picture.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HT5Ap39j",
      "url": "https://www.fiercepharma.com/pharma/trump-administration-teases-mfn-drug-pricing-rule-commitment-deadline-looms-companies",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 26, 2025 11:15am",
      "snippet": "The Trump administration is hinting at an upcoming rule aimed at implementing the President’s “most favored nation” drug pricing policy. The proposed policy is titled “global benchmark for efficient drug pricing (GLOBE) model” and no details were given beyond the title.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "eJkE1ytf",
      "url": "https://www.fiercepharma.com/pharma/trumps-100-pharmaceutical-tariff-threat-could-come-relief-analysts-note-many-drugmakers",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 26, 2025 10:01am",
      "snippet": "The 100% rate floated in Donald Trump’s new communique on pharmaceutical tariffs may appear steep, but the reality of the situation is likely less severe than it seems, multiple analysts wrote Friday following the president’s latest act of social media diplomacy.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "RQ8ov8Xi",
      "url": "https://www.fiercepharma.com/marketing/astrazeneca-joins-dtc-platform-pack-offering-70-discounts-farxiga-airsupra",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 26, 2025 10:52am",
      "snippet": "AstraZeneca is the latest Big Pharma to unveil a digital direct-to-consumer platform offering certain medicines at heavily reduced prices to cash-pay patients.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pubT56uy",
      "url": "https://www.fiercepharma.com/manufacturing/amgen-lays-out-650m-grow-puerto-rico-manufacturing-campus-add-hundreds-jobs",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 26, 2025 10:10am",
      "snippet": "Amgen has spent the last three decades building out its presence in Puerto Rico. With a $650 million investment revealed Friday, the company's site in Juncos is set to grow again.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "UjDUvqdf",
      "url": "https://www.fiercepharma.com/pharma/celltrion-lilly-plant-rexulti-ptsd-snub-glenmark-hengrui-adc-deal",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 26, 2025 9:41am",
      "snippet": "Celltrion is buying an Eli Lilly plant in the U.S. for $330 million. The FDA has declined to approve Lundbeck and Otsuka's Rexulti in PTSD. Hengrui Pharma has out-licensed certain rights to its HER2 ADC to Glenmark. And more.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "W2opkp7X",
      "url": "https://www.fiercepharma.com/pharma/asian-generics-powerhouse-lotus-expands-us-presence-acquisition-alvogen",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 26, 2025 8:16am",
      "snippet": "Serial entrepreneur Robert Wessman, who has had a golden touch creating, acquiring and spinning off companies that primarily sell generic drugs, has brought together two of his fastest-growing enterprises as Lotus Pharmaceuticals has&nbsp;acquired a 100% equity stake in Alvogen.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "gDfe55YZ",
      "url": "https://www.fiercepharma.com/pharma/crinetics-breaks-commercial-barrier-fda-nod-oral-acromegaly-drug-palsonify",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 25, 2025 2:22pm",
      "snippet": "The FDA on Thursday signed off on Crinetics’ paltusotine—now christened Palsonify—as a first-line treatment for certain adults with acromegaly. Unlike other somatostatin drugs that make up the bulk of current acromegaly care options, Palsonify is a small molecule, non-peptide the",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "ouj3cTax",
      "url": "https://www.fiercepharma.com/pharma/eli-lilly-oral-serd-inluriyo-passes-muster-fda-breast-cancer",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 25, 2025 3:15pm",
      "snippet": "Eli Lilly has won the second FDA approval for an oral selective estrogen receptor degrader (SERD), albeit in a confined breast cancer indication like Menarini's drug before it.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "2QO3_CMr",
      "url": "https://www.fiercepharma.com/pharma/hansa-eyes-accelerated-fda-review-after-posting-ph-3-win-kidney-transplant-drug-imlifidase",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 25, 2025 11:34am",
      "snippet": "Hansa Biopharma has reported positive top-line results from a U.S. phase 3 trial of its antibody-cleaving enzyme imlifidase, which boasts conditional nods in the EU and several other countries to ease the kidney transplant process for certain patients with end-stage renal disease",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "mhZcylRs",
      "url": "https://www.fiercepharma.com/pharma/scotus-appeal-astrazeneca-makes-last-gasp-challenge-against-medicare-price-program",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 25, 2025 10:26am",
      "snippet": "With an appeal to the Supreme Court, AstraZeneca is throwing one last Hail Mary following a string of Big Pharma defeats challenging the legality of the Inflation Reduction Act (IRA) Medicare price negotiation program.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "xgy5uBBI",
      "url": "https://www.fiercepharma.com/pharma/merck-kgaa-names-new-ceo-geopolitical-tension-roils-pharma-semiconductor-giant",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 25, 2025 10:16am",
      "snippet": "Belén Garijo, who steered Merck KGaA through the COVID-19 pandemic, will step down as CEO of the German healthcare and electronics conglomerate.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CmcxzVN4",
      "url": "https://www.fiercepharma.com/manufacturing/moderna-crowns-new-uk-facility-other-drugmakers-trash-kingdom",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 25, 2025 8:45am",
      "snippet": "Moderna has opened the doors to its long-anticipated Harwell vaccine production facility in the U.K. The facility debut comes as Moderna's competitors take shots at British life sciences policies and retreat from previously planned projects there.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.5,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "PgaYYuSi",
      "url": "https://www.fiercepharma.com/marketing/direct-patient-programs-are-works-94-pharmas-set-become-standard-practice-survey",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 24, 2025 2:42pm",
      "snippet": "The vast majority of drugmakers are either considering or have already established direct-to-patient programs, cutting out middlemen to offer services like virtual care consultations, payment support, at-home diagnostics and digital pharmacies.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "DyljPCC_",
      "url": "https://www.fiercepharma.com/pharma/acadia-grounds-hyperphagia-candidate-after-trial-failure-leaving-market-soleno",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 24, 2025 3:09pm",
      "snippet": "Soleno Therapeutics is breathing easier with a report from Acadia Pharmaceuticals that its candidate to treat hyperphagia in patients with Prader-Willi Syndrome has come up short in a phase 3 trial and has been scrapped by the company.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QqSvfzM4",
      "url": "https://www.fiercepharma.com/manufacturing/fujifilm-biotechnologies-cuts-ribbon-32b-antibody-facility-nc",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 24, 2025 12:02pm",
      "snippet": "Excitement around Fujifilm Biotechnologies’ massive new cell culture facility in Holly Springs, North Carolina, has been growing steadily since 2021, prompting a beefed-up investment from the company last April and a string of high-profile manufacturing contracts this year. Now, ",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "h6a9cX1H",
      "url": "https://www.fiercepharma.com/pharma/lilly-ceo-ricks-blasts-uk-its-drug-pricing-and-investment-environment",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 24, 2025 10:56am",
      "snippet": "As drugmakers are turning away from England, Eli Lilly CEO David Ricks&nbsp;has joined the chorus, calling it “probably the worst country in Europe” for drug pricing and adding that England is “not an attractive environment for investment.”",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1dyXDzgo",
      "url": "https://www.fiercepharma.com/pharma/potential-11b-deal-glenmark-grabs-certain-rights-hengrui-adc-rival-enhertu",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 24, 2025 9:50am",
      "snippet": "Hengrui Pharma’s dealmaking spree rolls on, with a potential $1.1 billion transaction on a rival to AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu being the latest addition.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CEVmKhfx",
      "url": "https://www.fiercepharma.com/pharma/biogen-plots-resubmission-after-fda-turns-down-high-dose-spinraza-sma-requests-more",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Sep 24, 2025 9:14am",
      "snippet": "The FDA has handed Biogen a complete response letter requesting that the company update “technical information” included in the chemistry, manufacturing and controls portion of its filing for high-dose Spinraza. Biogen said it aims to refile with the FDA \"promptly.\"",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "cKXEKlrZ",
      "url": "https://www.fiercebiotech.com/medtech/fda-clears-its-first-eyeglasses-slowing-childhood-nearsightedness-essilorluxottica",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 26, 2025 11:13am",
      "snippet": "The FDA handed a groundbreaking U.S. clearance to EssilorLuxottica and its eyeglasses to help slow the progression of nearsightedness in young children aged 6 to 12, including those with or without astigmatism.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "-oiXqwR7",
      "url": "https://www.fiercebiotech.com/biotech/biogen-officially-ends-all-aav-gene-therapy-work-prompting-team-restructure",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 26, 2025 11:04am",
      "snippet": "Biogen has discontinued all gene therapy programs using adeno-associated virus capsids, shifting resources to modalities that have the highest likelihood of achieving better treatment outcomes.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "E3y_E-eu",
      "url": "https://www.fiercebiotech.com/biotech/lilly-opens-latest-incubator-site-san-diego-several-biotechs-already-board",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 26, 2025 9:33am",
      "snippet": "While Eli Lilly is rethinking its biotech incubator plans in Europe, the Big Pharma has gone ahead and opened its San Diego site.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "M5Z-CgHO",
      "url": "https://www.fiercebiotech.com/biotech/us-biotechs-think-twice-about-licensing-drugs-europe-over-pricing-controversies",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 26, 2025 5:51am",
      "snippet": "U.S. biotechs are increasingly reluctant to license their drugs to European partners in order to avoid becoming a target of the Trump administration, industry insiders have told Fierce Biotech.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "PYuVkyJJ",
      "url": "https://www.fiercebiotech.com/medtech/trump-administration-launches-tariff-probe-medtech-industry",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 25, 2025 2:18pm",
      "snippet": "Known as a Section 232 investigation, the Commerce Department's work will cover everything from MRIs, robots and pacemakers to syringes, masks and gloves.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "_UQZmHd7",
      "url": "https://www.fiercebiotech.com/research/alternative-history-nih-shows-trump-level-defunding-would-have-undercut-breakthrough-drugs",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 25, 2025 12:06pm",
      "snippet": "An “alternative history” has revealed the potential impacts of a smaller National Institutes of Health on drug development—and the results paint a troubling picture.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "bJyzg5bo",
      "url": "https://www.fiercebiotech.com/medtech/sequel-med-tech-taps-arecor-test-its-twiist-pump-ultra-concentrated-insulin",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 25, 2025 12:16pm",
      "snippet": "The devicemaker will work with Arecor Therapeutics to develop its AT278 insulin, which packs 500 units to the milliliter—about five times as the most commonly used products today.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "Z7JBRG7S",
      "url": "https://www.fiercebiotech.com/biotech/nih-earmarks-87m-new-organoid-center-pivot-away-animal-testing-continues",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 25, 2025 11:42am",
      "snippet": "The National Institutes of Health is continuing its mission to reduce the use of animals in drug testing by awarding $87 million in contracts to launch the Standardized Organoid Modeling (SOM) Center, the agency announced in a Sept. 25 release.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zCHnmarG",
      "url": "https://www.fiercebiotech.com/biotech/eli-lilly-withdraws-phase-2b-trial-19b-obesity-bet-starting-enrollment",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 25, 2025 8:08am",
      "snippet": "Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a single patient, citing “strategic business reasons.” The study was designed to test bimagrumab, an asset Lilly acquired in its $1.9 billion Versanis buyout, as a single agent and in combination with bloc",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "taTGVwfb",
      "url": "https://www.fiercebiotech.com/biotech/heidelberg-lay-75-staff-after-milestone-becomes-millstone",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 25, 2025 7:06am",
      "snippet": "The FDA’s rejection of Telix Pharmaceuticals’ imaging agent has triggered layoffs at Heidelberg Pharma. With the regulatory setback delaying a $70 million payment, Heidelberg is reducing its workforce by 75% and narrowing its focus to extend its cash runway into the middle of nex",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "LQf3078a",
      "url": "https://www.fiercebiotech.com/biotech/evaxion-offloads-vaccine-candidate-merck-592-million-biobucks",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 24, 2025 3:58pm",
      "snippet": "Merck &amp; Co. is choosing to license one of Evaxion’s AI platform-based vaccine candidates, offering the Danish biotech up to $592 million for rights to the preclinical asset.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "3xo_lWoP",
      "url": "https://www.fiercebiotech.com/biotech/average-biopharma-biobucks-decline-while-upfront-deal-payments-rise-srs-acquiom",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 24, 2025 11:03am",
      "snippet": "While the average earnout potential per biopharma deal has declined over the last six years, the mean upfront value has been on the rise since 2017.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1d84IU4V",
      "url": "https://www.fiercebiotech.com/biotech/sparrow-flits-forward-95m-series-b-midstage-diabetes-asset",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 24, 2025 10:50am",
      "snippet": "Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of a $95 million series B, the company announced in a Sept. 24 release.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "K5bu5NtN",
      "url": "https://www.fiercebiotech.com/biotech/harmonys-pivotal-fragile-x-trial-flops-high-placebo-response-creates-discord",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 24, 2025 9:20am",
      "snippet": "Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. Two years after picking up ZYN002 despite a midphase flop, the biotech has reported that a registrational trial of the synthetic cannabidiol missed its primary endpoint.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "NGpT9Hi9",
      "url": "https://www.fiercebiotech.com/biotech/uniqure-hopes-launch-1st-huntingtons-gene-therapy-next-year-following-phase-12-success",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Sep 24, 2025 8:39am",
      "snippet": "UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was shown to slow progression of the neurodegenerative condition by 75% in a phase 1/2 trial",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "X5nILFeR",
      "url": "https://www.fiercepharma.com/pharma/regulatory-policy-uncertainties-are-hamstringing-biopharma-strategy-industry-execs-warn",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 7, 2025 3:25pm",
      "snippet": "This year has brought a range of challenges for biopharma companies and their leaders, including on-and-off tariff threats and President Donald Trump's arm-twisting around overseas drug spending. Now, new data show how industry leaders are grappling with these issues and others.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pNqP-OdN",
      "url": "https://www.fiercepharma.com/pharma/zenas-makes-big-bet-ms-drug-striking-2b-licensing-deal-innocare",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 8, 2025 11:27am",
      "snippet": "Eying a multiple sclerosis drug that it has tabbed with peak annual sales potential of $12 billion in the U.S. alone, Zenas BioPharma has struck a licensing deal with China-based InnoCare Pharma that could be worth more than $2 billion.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "V4w-pOrY",
      "url": "https://www.fiercepharma.com/marketing/vanda-signs-nhls-1st-pharma-patch-sponsor-islanders-deal-inks-dc-arena-partnership",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 8, 2025 11:25am",
      "snippet": "With a pair of new athletic partnerships under its belt, Vanda Pharmaceuticals is suiting up as a multisport player.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "kfIfbIbC",
      "url": "https://www.fiercepharma.com/pharma/vifor-cut-55-jobs-pa-parent-company-csl-pushes-ahead-downsizing-savings-campaign",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 8, 2025 9:03am",
      "snippet": "Vifor Pharma is letting go of 55 employees who report to the Swiss company’s primary U.S. office in King of Prussia, Pennsylvania, just outside Philadelphia, according to a Worker Adjustment and Retraining Notification Act report filed with the state. The job cuts are expected to",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "mN_DwA8l",
      "url": "https://www.fiercepharma.com/pharma/boehringer-ingelheim-breathes-new-life-lung-fibrosis-treatment-market-fda-approved-jascayd",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 7, 2025 5:07pm",
      "snippet": "Boehringer's Jascayd is the first new drug to break into the idiopathic pulmonary fibrosis field in more than a decade, following in the footsteps of the company's 2014-approved blockbuster Ofev.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "OXT-dKrB",
      "url": "https://www.fiercepharma.com/marketing/rising-stars-msls-kaylee-harrington-mind-blowing-experience-working-rural-health",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 7, 2025 2:49pm",
      "snippet": "In a Q&amp;A for Fierce Pharma Marketing’s “Rising Stars” series, Harrington talked about her personally and professionally rewarding work on the over-the-counter birth control medication Opill, the importance of partnering with trusted voices and her life in a cabin in the woods",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "RLPvtizY",
      "url": "https://www.fiercepharma.com/pharma/jury-orders-jj-pay-966m-baby-powder-lawsuit",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 7, 2025 2:54pm",
      "snippet": "A Los Angeles court found Johnson &amp; Johnson liable in a case brought by a woman who died from mesothelioma in 2021. With its decision, a jury ordered the company to pay $966 million to the family of Mae Moore.",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "cNZThNBu",
      "url": "https://www.fiercepharma.com/manufacturing/oxb-kicks-us-expansion-buying-viral-vector-plant-nc-national-resilience-45m",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 7, 2025 10:12am",
      "snippet": "Less than two months after OXB revealed a plan to expand its operations in the U.S., the U.K.-based cell and gene therapy manufacturer has purchased a viral vector plant in North Carolina from National Resilience for $4.5 million.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CYOLK08Z",
      "url": "https://www.fiercepharma.com/pharma/cdc-tweaks-guidance-covid-chickenpox-shots-vaccine-advisory-committee-recommendations",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 6, 2025 4:18pm",
      "snippet": "The CDC's updated COVID guidelines put the vaccines under an individual-based decision-making practice as opposed to the agency's prior universal recommendation.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "8joWEhpG",
      "url": "https://www.fiercepharma.com/marketing/tv-drug-ad-spending-picked-september-despite-federal-crackdown",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 6, 2025 4:51pm",
      "snippet": "Even as President Donald Trump directed the FDA in early September to begin cracking down on direct-to-consumer pharmaceutical advertising, spending on TV drug ads still ratcheted up compared to the preceding few months.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "zzmoeigd",
      "url": "https://www.fiercepharma.com/pharma/biogen-docked-124m-royalty-payments-cabilly-patent-dispute-genentech",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 6, 2025 3:15pm",
      "snippet": "A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that covered a process to manufacture monoclonal antibodies.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WNWhuyEs",
      "url": "https://www.fiercepharma.com/marketing/amgen-unveils-dtc-platform-60-discount-repatha-giving-us-lowest-price-g7-nations",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 6, 2025 11:03am",
      "snippet": "Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "vqPkrcs3",
      "url": "https://www.fiercepharma.com/pharma/az-daiichi-score-landmark-results-adc-datroway-triple-negative-breast-cancer",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 6, 2025 10:22am",
      "snippet": "AstraZeneca and Daiichi Sankyo’s Datroway has become the first cancer drug to show an overall survival benefit against chemotherapy for certain patients with a particularly aggressive form of breast cancer. In a phase 3 trial, the antibody-drug conjugate has scored as a first-lin",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "94KoaaS4",
      "url": "https://www.fiercepharma.com/marketing/myeloid-therapeutics-creates-new-identity-after-pipeline-outgrows-its-name",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 6, 2025 9:45am",
      "snippet": "Myeloid Therapeutics’ name no longer fits its pipeline. Having expanded beyond the eponymous myeloid cells, the biotech has rebranded as Create Medicines and committed to an R&amp;D strategy that spans in vivo multi-immune programming.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "XAj_Bjcm",
      "url": "https://www.fiercepharma.com/sponsored/discover-how-360deg-data-strategy-connects-patient-intent-provider-readiness-align",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 3, 2025 2:28pm",
      "snippet": "Patients and providers often enter the exam room misaligned. A 360° data strategy may be pharma’s missing link.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Fk5xtO6_",
      "url": "https://www.fiercebiotech.com/medtech/oxford-biodynamics-unveils-new-target-use-episwitch-blood-test",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 8, 2025 10:57am",
      "snippet": "Oxford BioDynamics, a U.K.-based maker of precision diagnostics, touted progress toward a first-of-its-kind blood test for chronic fatigue syndrome.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "aPLXBN1u",
      "url": "https://www.fiercebiotech.com/research/sanofi-inks-pact-canadian-tech-company-bring-ai-rd",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 8, 2025 11:55am",
      "snippet": "Sanofi has found a new preclinical research partner in Canadian software company BenchSci, which will provide the French drugmaker an AI copilot as part of a three-year partnership, BenchSci announced in an Oct. 8 release.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "78ktYtJg",
      "url": "https://www.fiercebiotech.com/biotech/transcode-rewrites-future-securing-25m-lifeline-and-phase-3-cancer-vaccine",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 8, 2025 9:03am",
      "snippet": "In a pair of deals, TransCode has bagged a phase 3 cancer vaccine and a $25 million injection into its cash-strapped coffers.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ssuBK6Kz",
      "url": "https://www.fiercebiotech.com/biotech/arthrosi-raises-153m-fueling-dash-toward-phase-3-gout-data-2026",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 8, 2025 9:53am",
      "snippet": "Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "mse-6cnq",
      "url": "https://www.fiercebiotech.com/biotech/langer-family-souffle-rises-200m-and-big-pharma-backed-rna-recipe",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 7, 2025 2:45pm",
      "snippet": "A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are targeted and cell-specific, the newly hatched company said in an Oct. 7 LinkedIn post.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "jeV0pBCl",
      "url": "https://www.fiercebiotech.com/biotech/us-government-bankrolls-48m-kernals-mrna-car-t",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 7, 2025 2:46pm",
      "snippet": "The financing will help Kernal advance its early-stage program KR-402 through clinical development in multiple sclerosis and B-cell malignancies.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5RISm280",
      "url": "https://www.fiercebiotech.com/biotech/james-wilsons-gemmabio-launches-new-gene-therapy-biotech-ultra-orphan-diseases",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 7, 2025 9:34am",
      "snippet": "Clinical setbacks and controversial pricing may have put a dampener on the gene therapy sector, but one of the industry’s pioneers is looking for a way forward.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "9WrGxyeq",
      "url": "https://www.fiercebiotech.com/medtech/eli-lilly-calls-urgent-improvements-europe-boost-diagnostic-testing-alzheimers-disease",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 7, 2025 7:43am",
      "snippet": "Eli Lilly is calling on European countries to make “urgent improvements” to their Alzheimer’s disease diagnostic testing practices just weeks after nabbing a new approval on the continent for its Alzheimer’s therapy Kisunla.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "TJRAQVAy",
      "url": "https://www.fiercebiotech.com/biotech/astrazenecas-13b-bet-yields-second-phase-3-blood-pressure-win-bolstering-differentiation",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 7, 2025 4:03am",
      "snippet": "AstraZeneca has hailed another phase 3 win for its blood pressure drug candidate baxdrostat, boosting its attempts to turn the molecule’s long half-life into a competitive advantage.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "q_6mOc5p",
      "url": "https://www.fiercebiotech.com/biotech/tcg-crossover-hauls-13b-third-investment-fund-four-years",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 6, 2025 11:15am",
      "snippet": "Bicoastal life sciences investment firm TCG Crossover has closed its third fund in about four years, securing $1.3 billion to bring its total capital raised to $3.1 billion.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "6OV2JrMa",
      "url": "https://www.fiercebiotech.com/medtech/icecure-medical-stock-jumps-fda-gives-green-light-breast-cancer-cryoablation-treatment",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 6, 2025 2:45am",
      "snippet": "IceCure Medical’s tumor-freezing treatment ProSense has nabbed FDA approval, making it the first medical device of its kind to be marketed for the local treatment of breast cancer.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "8W34Ofz6",
      "url": "https://www.fiercebiotech.com/biotech/cdmo-catalent-strengthens-adc-pipeline-10m-pact-lisata-tumor-drug",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 9, 2025 5:34am",
      "snippet": "Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate Lisata’s tumor drug.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "T_NYF-Ly",
      "url": "https://www.fiercebiotech.com/medtech/turbine-looks-turbo-charge-astrazenecas-adc-discovery",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Oct 6, 2025 4:16am",
      "snippet": "AstraZeneca is once again teaming up with Hungarian AI specialist Turbine as it looks to speed up and gain deeper insights into its antibody-drug conjugate discovery process.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "h9NWqOTE",
      "url": "https://www.fiercepharma.com/biotech/judge-knocks-down-pfizers-efforts-halt-novo-bid-metsera",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 5, 2025 5:15pm",
      "snippet": "Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout bid for the biotech, Bloomberg reports.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "djXTAI_b",
      "url": "https://www.fiercepharma.com/biotech/ftc-tells-novo-its-metsera-offer-may-violate-us-merger-law-current-form",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 5, 2025 4:02pm",
      "snippet": "In a letter to lawyers for Novo and Metsera, an FTC official wrote that the proposed purchase of Metsera by the Danish pharma \"may violate the procedural provisions\" of the Hart-Scott-Rodino (HSR) Act.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "_oLHmUrh",
      "url": "https://www.fiercepharma.com/manufacturing/supernus-pauses-new-patient-starts-parkinsons-pump-onapgo-citing-higher-expected",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 5, 2025 4:13pm",
      "snippet": "Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that patients’ appetite for the wearable is more than it can currently handle.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "Sg1wDRl6",
      "url": "https://www.fiercepharma.com/pharma/teva-steady-its-austedo-despite-ira-pressure-delivers-another-growth-quarter-backed-defining",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 5, 2025 11:27am",
      "snippet": "The company remains confident in the continued sales potential of Austedo after wrapping up government negotiations that will change the Medicare price for its top-seller in 2027.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "mj2WkFXy",
      "url": "https://www.fiercepharma.com/marketing/teva-drafts-nfl-star-terrell-davis-tardive-dyskinesia-awareness-drive",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 5, 2025 12:32pm",
      "snippet": "Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "-bh5lqWM",
      "url": "https://www.fiercepharma.com/pharma/amid-shaky-quarter-new-novo-chief-doustdar-says-companys-diabetes-and-obesity-turnaround",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 5, 2025 10:48am",
      "snippet": "Speaking to reporters during his first quarterly conference call at the company's helm, Maziar Mike Doustdar made clear that expanding access to Novo’s GLP-1 medicines—and continuing to unlock novel sales channels—will be key as the Danish drugmaker aims to address its recent gro",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "x_N7-Tix",
      "url": "https://www.fiercepharma.com/pharma/sales-booming-amgen-wants-us-biosimilar-landscape-remain",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 5, 2025 7:40am",
      "snippet": "With its biosimilars business thriving, Amgen is in a unique position to comment on U.S. biosimilar policy as the current administration introduces reforms to increase the availability of the copycat drugs. As officials discuss easing biosim regulatory standards, Amgen execs shar",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ftPIG2FG",
      "url": "https://www.fiercepharma.com/marketing/rising-stars-why-ucbs-katie-swicegood-fulp-made-leap-consumer-pharma-marketing",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 4, 2025 2:41pm",
      "snippet": "In a Q&amp;A for Fierce Pharma Marketing’s “Rising Stars” series, Swicegood Fulp reflected on the route that led to her current role as media and digital direct-to-consumer marketing lead at UCB.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "6bWbRLbY",
      "url": "https://www.fiercepharma.com/pharma/pfizers-prevnar-abrysvo-and-comirnaty-suffer-q3-sales-declines-amid-tough-us-market-vaccines",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 4, 2025 2:15pm",
      "snippet": "Even without accounting for the COVID-related declines that have punctuated Pfizer’s earnings in recent years, the company’s vaccines business appeared to be on the back foot in the third quarter, brought low by a U.S. market that is currently proving unfavorable for immunization",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "8O-oYpen",
      "url": "https://www.fiercepharma.com/biotech/publishers-note-questex-acquisition-supercharges-fierce-portfolio-conference-forum-and",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 4, 2025 12:00pm",
      "snippet": "Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening the leaders shaping clinical innovation, competitive intelligence, market research and the future of drug delivery.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "GcfyNuok",
      "url": "https://www.fiercepharma.com/pharma/roll-ucb-picks-another-rare-disease-fda-approval",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 4, 2025 11:00am",
      "snippet": "UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian company, which has scored three nods in the U.S. for rare disease treatments in less than three years.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "xjco0QdJ",
      "url": "https://www.fiercepharma.com/manufacturing/teva-recalls-more-half-million-bottles-blood-pressure-med-possible-carcinogens",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 4, 2025 7:59am",
      "snippet": "Teva issued a voluntary recall of 580,844 bottles of the widely used blood pressure medication prazosin hydrochloride, citing unacceptable levels of potentially cancer-causing impurities. ",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "SkZOUXa-",
      "url": "https://www.fiercepharma.com/biotech/merck-writes-tale-2-checks-bagging-700m-blackstone-while-spending-150m-regain-asset",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 4, 2025 8:40am",
      "snippet": "Merck &amp; Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive pivotal oncology push.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "5FYxw6M1",
      "url": "https://www.fiercepharma.com/pharma/sarepta-pushes-full-approval-duchenne-drugs-despite-missed-confirmatory-trial-goal",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 3, 2025 9:14pm",
      "snippet": "A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal. The development comes just as the company and the FDA work to formally limit the indication of another Sarepta product, the gene therapy Elevidys.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "yvLgPYYE",
      "url": "https://www.fiercepharma.com/manufacturing/alvotech-plant-foils-another-fda-review-time-teva-partnered-simponi-biosimilar",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 3, 2025 5:04pm",
      "snippet": "Patients hoping to get their hands on a cheaper copycat of Johnson &amp; Johnson’s fading anti-inflammatory blockbuster Simponi may have to wait for a few months more, thanks to an FDA inspection this summer that has derailed a leading biosimilar application from partners Teva an",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "MUtBo_hx",
      "url": "https://www.fiercepharma.com/marketing/pharmas-corporate-reputation-dips-among-neurology-patient-groups-citing-drug-access",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 3, 2025 11:36am",
      "snippet": "Neurology-focused patient groups’ perception of the pharma industry’s corporate reputation remains on a downward slope.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "BYlRvfGj",
      "url": "https://www.fiercepharma.com/pharma/kimberly-clark-buys-out-kenvue-487b-consumer-health-merger",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 3, 2025 11:36am",
      "snippet": "Kimberly-Clark has placed an ambitious bet on a troubled counterpart, agreeing to buy out Johnson &amp; Johnson’s consumer health spinout Kenvue for $48.7 billion.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "kli3uVjs",
      "url": "https://www.fiercebiotech.com/biotech/dynavax-pays-vaxart-25m-oral-covid-19-vaccine-program",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 5:02am",
      "snippet": "Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the program.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "jGikqDqh",
      "url": "https://www.fiercebiotech.com/medtech/icecures-cryoablation-treatment-may-extend-survival-some-lung-cancer-patients-study-finds",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 3:56am",
      "snippet": "Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined with radiation may extend survival for patients with an inoperable form of lung can",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "JENsetZ0",
      "url": "https://www.fiercebiotech.com/biotech/astrazeneca-drops-phase-2-stage-mash-drug-over-disappointing-data",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 5:22am",
      "snippet": "AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "AZ-d6Qxq",
      "url": "https://www.fiercebiotech.com/biotech/judge-knocks-down-pfizers-efforts-halt-novo-bid-metsera",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 5, 2025 5:15pm",
      "snippet": "Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout bid for the biotech, Bloomberg reports.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "g-Bb3QRC",
      "url": "https://www.fiercebiotech.com/biotech/ftc-tells-novo-its-metsera-offer-may-violate-us-merger-law-current-form",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 5, 2025 4:02pm",
      "snippet": "In a letter to lawyers for Novo and Metsera, an FTC official wrote that the proposed purchase of Metsera by the Danish pharma \"may violate the procedural provisions\" of the Hart-Scott-Rodino (HSR) Act.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "HZJVrDpp",
      "url": "https://www.fiercebiotech.com/medtech/dexcom-hit-fda-class1-recall-its-continuous-glucose-monitoring-system-app",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 5, 2025 4:43am",
      "snippet": "Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "5a9fabQE",
      "url": "https://www.fiercebiotech.com/biotech/braveheart-bio-mission-conquer-heart-disease-market-captures-185m-series",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 4, 2025 4:42pm",
      "snippet": "The hypertrophic-cardiomyopathy-focused biotech is led by former HI-Bio founder and CEO Travis Murdoch, M.D., while Biogen's CEO Chris Viehbacher chairs the board of directors.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "_7znosAd",
      "url": "https://www.fiercebiotech.com/biotech/novo-drops-oncology-ambitions-early-stage-mash-prospects-ongoing-rd-shake",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 5, 2025 7:22am",
      "snippet": "Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish Pharma’s ambitious restructuring.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "n6SN45BE",
      "url": "https://www.fiercebiotech.com/biotech/lilly-pulls-out-cns-portion-950m-rirpk1-inhibitor-collab-rigel",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 5, 2025 5:27am",
      "snippet": "Eli Lilly has pulled out of the central-nervous-system-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 inhibitors.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "AoTtjfm-",
      "url": "https://www.fiercebiotech.com/biotech/lilly-expands-xtalpi-collaboration-345m-antibody-development-pact",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 4, 2025 2:29pm",
      "snippet": "Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery shop as much as $345 million.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Jjs1jS5f",
      "url": "https://www.fiercebiotech.com/biotech/amgen-halts-gastric-cancer-trial-after-antibody-did-not-meet-our-standard-efficacy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 4, 2025 5:41pm",
      "snippet": "Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has stopped another trial of the molecule.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "yAdBXovu",
      "url": "https://www.fiercebiotech.com/biotech/novo-nordisk-ceo-feels-danish-pharma-will-bag-metsera-end-pfizer-bidding-war",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 5, 2025 4:21am",
      "snippet": "Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera but said the Big Pharma “feels this deal will be closed.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "oTrKxq99",
      "url": "https://www.fiercebiotech.com/biotech/fda-rejects-biohaven-approval-request-triggering-cost-cutting",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 5, 2025 4:04am",
      "snippet": "The FDA has rejected Biohaven’s request for approval of a neurological disorder therapy, prompting the biopharma to reprioritize its pipeline.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "IufvckhI",
      "url": "https://www.fiercebiotech.com/biotech/billionaire-backed-arena-bioworks-shutters-less-2-years-after-launch-cites-biotech-macro",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 4, 2025 5:22pm",
      "snippet": "Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as the reason for the sudden closure.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "VamaBOGz",
      "url": "https://www.fiercebiotech.com/biotech/pfizers-parade-pipeline-cuts-seagen-biontech-and-mash-programs-among-11-axed",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 4, 2025 1:58pm",
      "snippet": "Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage MASH combo.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "X9Y0S6DM",
      "url": "https://www.fiercebiotech.com/medtech/qiagen-ceo-step-down-company-snaps-parse-biosciences-225-million-upfront-deal",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 4, 2025 1:55pm",
      "snippet": "The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, it also revealed that its long-term chief executive, Thierry Bernard, will step down while also opening its wallet for a new acquisition.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "6OxFYquD",
      "url": "https://www.fiercebiotech.com/biotech/publishers-note-questex-acquisition-supercharges-fierce-portfolio-conference-forum-and",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 4, 2025 12:00pm",
      "snippet": "Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening the leaders shaping clinical innovation, competitive intelligence, market research and the future of drug delivery.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "UE0Kz-KW",
      "url": "https://www.fiercepharma.com/pharma/jjs-caplyta-supersizes-its-reach-lucrative-expansion-major-depressive-disorder",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Oct 31, 2025 2:39pm",
      "snippet": "Caplyta, the crown jewel of Johnson &amp; Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to unlock the lucrative major depressive disorder market as an adjunctive treatment to antidepressants.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "86kWXIwT",
      "url": "https://www.fiercebiotech.com/medtech/registrar-snaps-cmc-medical-devices-expand-global-compliance-offering",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 7:38am",
      "snippet": "Registrar Corp., a unit of Paine Schwartz Partners, acquired Spanish medical device consulting services provider CMC Medical Devices, expanding the U.S.-based compliance specialist's global reach.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "-9G_2PEi",
      "url": "https://www.fiercebiotech.com/biotech/eli-lilly-links-amylin-agonist-20-weight-loss-sparking-charge-phase-3",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 7:38am",
      "snippet": "Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zokUYllF",
      "url": "https://www.fiercebiotech.com/biotech/modernas-norovirus-phase-3-study-heads-north-again-after-struggling-find-cases",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 7:40am",
      "snippet": "First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere after failing to find enough cases down south.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "YVBe-WS5",
      "url": "https://www.fiercebiotech.com/biotech/inflammation-biotech-evommune-heads-nyse-150m-ipo",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 5:45am",
      "snippet": "Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO that the inflammation biotech will use to fund a pair of clinical-stage candidates.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ngYe3pCU",
      "url": "https://www.fiercebiotech.com/biotech/urogen-hands-anti-ctla4-back-agenus-after-being-unimpressed-phase-1-data",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 9:12am",
      "snippet": "UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding that phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "RldTuIXH",
      "url": "https://www.fiercepharma.com/marketing/jj-brings-invisible-illness-ibd-out-shadows-report-supporting-power-patient-community",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 7, 2025 4:11pm",
      "snippet": "Patient advocacy communities such as Johnson &amp; Johnson's IBD Social Circle can quell the feelings of loneliness and isolation common in those with IBD, the company explains in a new report.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "dQPZgrn5",
      "url": "https://www.fiercepharma.com/pharma/regeneron-az-see-green-lights-after-separate-ph-3-wins-fasenra-dupixent-tough-treat",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 7, 2025 11:30am",
      "snippet": "At the American College of Allergy, Asthma and Immunology’s annual meeting this week, two drug juggernauts showcased promising data on their respective anti-inflammatory blockbusters, bolstering approval ambitions at the FDA.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "cUY_QoFW",
      "url": "https://www.fiercepharma.com/marketing/tv-ad-spending-skyrocketed-new-heights-october-led-record-outlay-jjs-tremfya",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 7, 2025 11:41am",
      "snippet": "After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way last month.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "ZtseocTB",
      "url": "https://www.fiercepharma.com/manufacturing/precheck-pulse-check-what-industry-saying-about-fdas-production-initiative",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 6, 2025 3:58pm",
      "snippet": "This week on “The Top Line,” we break down what’s known about FDA’s PreCheck, and the parts of the plan that could have the biggest impact on manufacturers.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "kWTTMOAH",
      "url": "https://www.fiercepharma.com/biotech/amid-metsera-contest-novo-ceo-tells-pfizer-bid-higher-if-it-wants-win",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 7, 2025 9:21am",
      "snippet": "Amid Novo Nordisk and Pfizer’s whiplash bidding war for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "X0kIo35j",
      "url": "https://www.fiercepharma.com/marketing/merck-foundation-pumps-22m-heart-health-equity-programs",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 7, 2025 8:14am",
      "snippet": "Merck &amp; Co.’s charitable foundation has committed $22 million to efforts to improve access to care for people with heart disease in the U.S.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "8SZcooxN",
      "url": "https://www.fiercepharma.com/pharma/lilly-ai-drug-design-deal-celltrion-autoimmune-pact-china-lift-illumina-ban",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 7, 2025 9:28am",
      "snippet": "Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune candidates. China will lift the import ban on Illumina's DNA sequencers. And more.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "nY1FtpGO",
      "url": "https://www.fiercepharma.com/pharma/fda-approves-jj-darzalex-first-treatment-smoldering-multiple-myeloma",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 6, 2025 4:13pm",
      "snippet": "The approval of Darzalex in smoldering multiple myeloma also offers drugmakers some relief, because the drug’s proposed use had previously drawn criticism from Vinay Prasad, M.D., before he joined the FDA.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "95muJ5db",
      "url": "https://www.fiercepharma.com/providers/providers-lawsuit-against-rfk-now-asks-court-nullify-acips-recent-vaccine-recommendations",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 6, 2025 3:34pm",
      "snippet": "An amended complaint from several provider associations argues the vaccine advisory committee's new members were appointed for their anti-vaccine biases, not their experience or credentials, and should be removed under statute and the advisory body's charter.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "4IzbH4Nv",
      "url": "https://www.fiercepharma.com/biotech/fda-announces-second-round-priority-voucher-winners-including-glp-1-leaders-lilly-and-novo",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 6, 2025 2:48pm",
      "snippet": "The FDA has released the second batch of recipients for the new \"national priority voucher\" program, with executives for two of the beneficiaries appearing in the Oval Office with President Donald Trump Nov. 6.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "IrdYMEuW",
      "url": "https://www.fiercepharma.com/pharma/eli-lilly-novo-nordisk-strike-deal-white-house-cut-price-weight-loss-drugs",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 6, 2025 12:11pm",
      "snippet": "Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "wK8GuFbp",
      "url": "https://www.fiercepharma.com/pharma/astrazeneca-ceo-we-can-absorb-impact-drug-pricing-deal-trump",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 6, 2025 10:46am",
      "snippet": "The “most favored nation” drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the British pharma’s $80 billion revenue target by 2030, CEO Pascal Soriot said.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Lbj06glC",
      "url": "https://www.fiercebiotech.com/biotech/amid-metsera-contest-novo-ceo-tells-pfizer-bid-higher-if-it-wants-win",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 7, 2025 9:21am",
      "snippet": "Amid Novo Nordisk and Pfizer’s whiplash bidding war for obesity biotech Metsera, Novo’s CEO has, quite literally, told its rival to put its money where its mouth is.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "TbeF8AE9",
      "url": "https://www.fiercebiotech.com/biotech/sana-camp4-ditch-clinical-stage-assets-more-promising-preclinical-candidates",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 7, 2025 5:40am",
      "snippet": "Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their pipelines on the most promising candidates.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Ka5W6u2H",
      "url": "https://www.fiercebiotech.com/biotech/patient-dies-after-receiving-intellias-crispr-therapy",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 7, 2025 4:57am",
      "snippet": "The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. Both phase 3 studies of the candidate remain on hold as the biotech works to understand liver-related events seen in the trials and to develop a risk-mitigation plan.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "zs02idgY",
      "url": "https://www.fiercebiotech.com/research/needle-haystack-experiments-reveal-targets-new-tuberculosis-vaccines",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 11:11pm",
      "snippet": "Painstaking experiments have revealed the cellular signatures that signify a tuberculosis infection, providing a series of targets for new vaccines that could finally subdue one of the world’s leading killers.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1X8DQ2XL",
      "url": "https://www.fiercebiotech.com/biotech/fda-announces-second-round-priority-voucher-winners-including-glp-1-leaders-lilly-and-novo",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 2:48pm",
      "snippet": "The FDA has released the second batch of recipients for the new \"national priority voucher\" program, with executives for two of the beneficiaries appearing in the Oval Office with President Donald Trump Nov. 6.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "zonYhxMV",
      "url": "https://www.fiercebiotech.com/biotech/cullinan-sidelines-pair-oncology-assets-amid-expansion-autoimmune-rd",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 6, 2025 12:47pm",
      "snippet": "More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "MDhyV8FZ",
      "url": "https://www.fiercebiotech.com/biotech/pfizer-beats-out-novo-10b-agreement-buy-metsera",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 8, 2025 8:02am",
      "snippet": "After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "hFk1yc3E",
      "url": "https://www.fiercepharma.com/manufacturing/astrazeneca-boosts-its-presence-maryland-2b-manufacturing-investment",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 21, 2025 3:39pm",
      "snippet": "Maryland is becoming the home away from home for British drugmaker AstraZeneca. On Friday, the biopharma powerhouse upped its ante in the Old Line State, saying it will invest $2 billion to increase its manufacturing presence there.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "AQfs8UMn",
      "url": "https://www.fiercepharma.com/pharma/fda-grants-game-changing-perioperative-approval-padcev-keytruda-combo-bladder-cancer",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 21, 2025 1:09pm",
      "snippet": "The approval came \"months earlier than&nbsp;anticipated,\" Pfizer's Chief Oncology Officer, Jeff Legos, Ph.D., said in a statement.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "roXuGIv2",
      "url": "https://www.fiercepharma.com/pharma/fda-launches-investigation-takedas-adzynma-following-reported-pediatric-death",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 21, 2025 11:25am",
      "snippet": "The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "HljrEp3-",
      "url": "https://www.fiercepharma.com/pharma/australian-government-rejects-cosettes-proposed-mayne-pharma-buyout-citing-national-interest",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 21, 2025 11:00am",
      "snippet": "Cosette had been attempting to invalidate its $430 million buyout of Australia's Mayne Pharma since May and has now seen its wish granted based on a national security concern from the Australian government.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "UNVzqdvV",
      "url": "https://www.fiercepharma.com/marketing/semaglutide-compounder-drops-claims-after-novo-nordisk-challenge",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 21, 2025 4:46am",
      "snippet": "A Novo Nordisk challenge has driven Regen Doctors to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against companies selling versions of its GLP-1 blockbuster.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "y6ithE1I",
      "url": "https://www.fiercepharma.com/pharma/2025s-fiercest-women-life-sciences-are-changing-game",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 19, 2025 2:47pm",
      "snippet": "In this episode of “The Top Line,” Fierce’s Andrea Park and Gabrielle Masson unpack this year’s Fiercest Women in Life Sciences report.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "2PNkAymL",
      "url": "https://www.fiercepharma.com/pharma/fierce-pharma-asia-us-china-supply-chain-ties-bayer-biotech-incubator-henlius-biosim-nod",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 1:21pm",
      "snippet": "A new report finds China supplies many key pharmaceutical ingredients to the U.S. market. Bayer opened a new biotech incubator in Beijing. A first-of-its-kind biosimilar originally developed by Shanghai Henlius Biotech scored FDA approval. And more.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "Uq-JIpK8",
      "url": "https://www.fiercepharma.com/providers/cdc-updates-autism-claims-website",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 3:25pm",
      "snippet": "Changes to a public health webpage undercut the medical community's consensus rebuke of childhood vaccines as a cause of autism. They were swiftly condemned by public health advocates and the Senate's top healthcare legislator.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "uYloaaAu",
      "url": "https://www.fiercepharma.com/pharma/moderna-takes-15b-loan-outlines-new-commercial-and-rd-strategy-bid-break-even-2028",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 2:15pm",
      "snippet": "In an effort to break even by 2028, mRNA specialist Moderna is laying out a three-year business strategy, highlighting promising avenues for growth and setting out a goal to lift revenue by up to 10% in 2026.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "UbQHRvIl",
      "url": "https://www.fiercepharma.com/pharma/2-fda-nods-eylea-hd-regeneron-no-longer-fighting-vabysmo-both-hands-tied-behind-its-back",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 10:56am",
      "snippet": "After months of back-and-forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing option for the eye disease drug.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "6Gn0Smbj",
      "url": "https://www.fiercepharma.com/pharma/pfizer-tris-pharma-ink-415m-deal-settle-adulterated-adhd-drug-allegations-texas",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 11:03am",
      "snippet": "Pfizer and manufacturer Tris Pharma were accused in 2023 of previously providing ADHD med Quillivant through the Texas Medicaid program despite knowing that the drug failed quality control tests during production.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "jibTZSib",
      "url": "https://www.fiercepharma.com/marketing/sun-pharma-shines-light-diabetic-retinopathy-seebeyondsugar-campaign",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 11:24am",
      "snippet": "Sun Pharma has launched an eye-opening awareness push about a common—and commonly overlooked—complication of diabetes.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "YHjSHKVU",
      "url": "https://www.fiercepharma.com/manufacturing/indian-api-maker-cdymax-hit-warning-letter-related-raw-material-testing",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 8:09am",
      "snippet": "Cdymax Pharma has been slapped with a warning letter from the FDA outlining two observations against the Bangalore, India-based API maker, both linked to testing shortfalls. ",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.6000000000000001,
      "assigned_to": "CCO",
      "high_priority": true,
      "keyword_matches": 1,
      "impact": "medium",
      "urgency": "immediate"
    },
    {
      "id": "62mYkmuq",
      "url": "https://www.fiercepharma.com/manufacturing/biomanufacturer-antheia-bolsters-commercial-drug-ingredients-prospects-tapi-alliance",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 19, 2025 2:06pm",
      "snippet": "Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "80GuNs0T",
      "url": "https://www.fiercepharma.com/manufacturing/moderna-will-spend-140m-build-new-us-manufacturing-facility",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 19, 2025 2:35pm",
      "snippet": "With a $140 million investment, Moderna will build a new facility at its manufacturing campus in Norwood, Massachusetts. The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "1FySyIa8",
      "url": "https://www.fiercepharma.com/pharma/after-lundbecks-surprise-bid-alkermes-sweetens-deal-acquire-avadel",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 19, 2025 9:36am",
      "snippet": "Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22.50 per Avadel share to acquire the company. Both drugmakers’ boards have blessed the amended deal and currently expect the acquisition, which values Avadel at up to $2.37 billion, to c",
      "kind": "market",
      "category": "market",
      "priority": 0.45,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 1,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "epQyYdRQ",
      "url": "https://www.fiercepharma.com/pharma/teva-calls-startups-rise-occasion-new-open-innovation-platform-targeting-7-biopharma",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 18, 2025 4:15pm",
      "snippet": "Teva Pharmaceutical is launching its first global innovation platform, challenging startups to submit novel strategies to tackle seven industry hurdles that run the gamut from manufacturing to R&amp;D.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "XafblAUX",
      "url": "https://www.fiercepharma.com/marketing/rising-stars-how-spectrum-sciences-ali-sullivan-fell-pharma-marketing",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 18, 2025 3:24pm",
      "snippet": "In a Q&amp;A for Fierce Pharma Marketing’s “Rising Stars” series, Sullivan reflected on her work on a celebrity-fronted branded campaign and discussed the importance of staying open to new ideas, even from unexpected sources.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "MMuFBx-n",
      "url": "https://www.fiercebiotech.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 21, 2025 4:16pm",
      "snippet": "Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were concerned about the FDA’s ability to function.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "7dhH7V7-",
      "url": "https://www.fiercebiotech.com/biotech/fda-kicks-hiring-spree-and-new-communication-program-speed-sluggish-drug-reviews",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 21, 2025 11:20am",
      "snippet": "The FDA is hiring more than 1,000 new employees and rolling out a pilot communication program in an effort to speed up the review of new drugs.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "wthzTKvx",
      "url": "https://www.fiercebiotech.com/medtech/ge-healthcare-acquire-imaging-software-provider-intelerad-23b",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 20, 2025 4:35pm",
      "snippet": "With its focus on radiology and cardiology practices, as well as assisting in clinical trials, Intelerad’s outpatient footprint will serve as a complement to GE HealthCare’s in-hospital imaging business.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "YKOH8xXN",
      "url": "https://www.fiercebiotech.com/providers/cdc-updates-autism-claims-website",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 20, 2025 3:25pm",
      "snippet": "Changes to a public health webpage undercut the medical community's consensus rebuke of childhood vaccines as a cause of autism. They were swiftly condemned by public health advocates and the Senate's top healthcare legislator.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "CerkYHDo",
      "url": "https://www.fiercebiotech.com/biotech/modernas-reshaping-rolls-3-more-pipeline-purges",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 20, 2025 3:36pm",
      "snippet": "Moderna, an mRNA specialist known for its COVID-19 vaccine Spikevax, is winding down development of three clinical mRNA programs, including two investigational vaccines for infectious diseases.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "OeQtsZcJ",
      "url": "https://www.fiercebiotech.com/biotech/pfizer-details-phase-3-data-mrna-flu-vaccine",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 20, 2025 11:02am",
      "snippet": "Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot securing 34.5% greater effectiveness compared to a control vaccine.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "Gs0IlIx6",
      "url": "https://www.fiercebiotech.com/medtech/abbott-dives-cancer-diagnostics-23b-buyout-exact-sciences",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 20, 2025 10:14am",
      "snippet": "Abbott has signed up to buy Exact Sciences in the largest diagnostics deal to date, acquiring the maker of the Cologuard at-home screening test for colorectal cancer and new blood-based tests for multiple tumors.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "7CcYYb0R",
      "url": "https://www.fiercebiotech.com/biotech/applied-lays-46-workforce-rare-disease-drug-approval-looks-out-reach",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 20, 2025 8:39am",
      "snippet": "Facing skepticism from analysts about whether it has the resources to take its rare disease drug to market, Applied Therapeutics is laying off almost half its workforce to conserve its remaining cash.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "tHS9_whO",
      "url": "https://www.fiercebiotech.com/biotech/aspen-enriches-parkinsons-cell-therapy-trial-kite-backed-115m-series-c",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 19, 2025 5:04pm",
      "snippet": "Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraising that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "hf5gSEVl",
      "url": "https://www.fiercebiotech.com/biotech/3b-deal-merck-kgaa-becomes-latest-big-pharma-partner-drug-discoverer-valo-health",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 19, 2025 2:19pm",
      "snippet": "Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The German drugmaker has inked a deal to harness Valo’s reams of human biology data to find new therapeutic targets for Parkinson’s disease, offering a potential ",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "MJAFIuLj",
      "url": "https://www.fiercebiotech.com/biotech/gsk-picks-flagships-quotient-profound-1st-biotech-partners-7b-pact",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 19, 2025 3:35pm",
      "snippet": "GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering.&nbsp;",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "fhF_IUpQ",
      "url": "https://www.fiercebiotech.com/biotech/novartis-ceo-paid-top-dollar-avidity-become-leader-neuromuscular-diseases",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 20, 2025 4:38am",
      "snippet": "Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the company’s CEO sees it—it’s never about the price tag.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "pQi9aSpx",
      "url": "https://www.fiercepharma.com/pharma/azs-imfinzi-expands-its-perioperative-prowess-early-stage-stomach-cancer-fda-nod",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 4:23pm",
      "snippet": "The FDA signed off on Imfinzi as the first immunotherapy that can treat certain patients with early-stage stomach cancer both before and after surgery, marking the drug's third perioperative nod.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "s_Qt8LMu",
      "url": "https://www.fiercepharma.com/marketing/calling-all-rising-stars-pharma-marketing-nominations-open-fierce-feature-series",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 2:21pm",
      "snippet": "Nominate up-and-coming early-career pharma marketing pros here to be featured in Fierce's \"Rising Stars\" Q&amp;A series.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "IFZM3cqw",
      "url": "https://www.fiercepharma.com/pharma/sarepta-gets-fdas-go-ahead-add-new-immunosuppressive-regimen-elevidys-study-key-population",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 1:05pm",
      "snippet": "Sarepta will study its gene therapy Elevidys with the immunosuppressant sirolimus in non-ambulatory patients with Duchenne muscular dystrophy in the hopes of quelling the liver safety issues that led to a label restriction.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "JCgFhmjT",
      "url": "https://www.fiercepharma.com/marketing/pharma-pros-skeptical-letting-ai-loose-regulatory-compliance-submissions-survey",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 11:00am",
      "snippet": "A survey has found that pharma marketing and promotional review professionals are skeptical of the outputs of artificial intelligence models, with 65% of respondents saying they don’t trust the technology to create regulatory compliance submissions.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QnzjKoPL",
      "url": "https://www.fiercepharma.com/biotech/questions-swirl-over-fdas-national-priority-voucher-program-2-lawmakers-push-answers",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 9:40am",
      "snippet": "Amid a groundswell of questions and pushback over the FDA's Commissioner's National Priority Voucher program, two lawmakers are seeking to gain more clarity.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "BcDAl-Ak",
      "url": "https://www.fiercepharma.com/manufacturing/novartis-lays-out-plan-cut-550-jobs-plant-switzerland-end-2027",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 9:53am",
      "snippet": "Less than a week after Novartis unveiled a plan to establish a “flagship manufacturing hub” in North Carolina that would add 700 employees to its rolls, the Swiss drugmaker says it is making moves in its home country that will eliminate 550 jobs at one site and add 80 at another ",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "H8fjHVKU",
      "url": "https://www.fiercepharma.com/pharma/novartis-scores-fda-approval-new-version-sma-gene-therapy-prices-259m",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 10:11am",
      "snippet": "Novartis has received an FDA approval for Itvisma, an intrathecal version of the company’s gene therapy Zolgensma, to treat older patients with spinal muscular atrophy.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "4rPgCIbW",
      "url": "https://www.fiercepharma.com/marketing/angelini-faces-watchdogs-wrath-after-speaker-blasts-stupid-ema",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 25, 2025 5:20am",
      "snippet": "The PMCPA has ruled that a presentation calling the European Medicines Agency “stupid” brought discredit on the pharma industry.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "2OlptaxZ",
      "url": "https://www.fiercepharma.com/marketing/sk-life-science-xcopri-ad-meets-roadblock-fda-untitled-letter",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 24, 2025 11:57am",
      "snippet": "A few months after SK Life Science began rolling out a road trip-themed TV commercial for its antiseizure medication Xcopri, the FDA is attempting to put the brakes on the ad.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "8xOmOLg-",
      "url": "https://www.fiercepharma.com/pharma/novos-shares-tumble-8-after-2-trial-misses-semaglutide-alzheimers-disease",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 24, 2025 11:08am",
      "snippet": "Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "048TDYAR",
      "url": "https://www.fiercepharma.com/pharma/merck-partner-kelun-touts-phase-3-win-adc-keytruda-combo-first-line-lung-cancer",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 24, 2025 10:19am",
      "snippet": "A combination of Merck-partnered sac-TMT and Keytruda led to a “statistically significant and clinically meaningful” improvement in progression-free survival versus Keytruda alone in a phase 3 trial in first-line PD-L1-positive NSCLC, Kelun said Monday.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "MctNc55y",
      "url": "https://www.fiercepharma.com/pharma/q3-drugmakers-saw-marked-decline-vaccine-sales-especially-us",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 20, 2025 4:20pm",
      "snippet": "The commercial effects of an emboldened anti-vaccine movement in the U.S. were evident in the third quarter as several companies reported declining vaccine sales.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zlBocWQy",
      "url": "https://www.fiercepharma.com/marketing/lilly-levels-alzheimers-awareness-chris-hemsworth-collab-major-media-buys",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 21, 2025 4:34pm",
      "snippet": "Eli Lilly's latest high-profile crossovers—which include a starry TV partnership and the far-reaching rollout of a new campaign—both tie into the drugmaker’s work to draw more attention to Alzheimer’s disease.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "QcHb-gyY",
      "url": "https://www.fiercepharma.com/biotech/letter-makary-biotech-ceos-push-fda-stability-and-say-volatility-threatens-us-innovation",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 21, 2025 4:16pm",
      "snippet": "Hundreds of industry leaders have signed a letter to FDA Director Marty Makary, M.D., about the importance of having a predictable regulatory agency, citing a survey in which 82% of biopharma respondents said they were concerned about the FDA’s ability to function.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "CjjfboHM",
      "url": "https://www.fiercebiotech.com/biotech/abbvie-launches-lab-space-innovation-program-quebec-biotechs",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 25, 2025 11:31am",
      "snippet": "AbbVie is opening up submissions for an award that will provide one Canadian biotech free access to lab space and executive insights from the Big Pharma.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "WFeAHk4G",
      "url": "https://www.fiercebiotech.com/biotech/questions-swirl-over-fdas-national-priority-voucher-program-2-lawmakers-push-answers",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 25, 2025 9:40am",
      "snippet": "Amid a groundswell of questions and pushback over the FDA's Commissioner's National Priority Voucher program, two lawmakers are seeking to gain more clarity.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "F_-oqkjc",
      "url": "https://www.fiercebiotech.com/biotech/sarepta-shares-positive-safety-update-dm1-asset-arrowhead-hits-200m-milestone",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 24, 2025 3:18pm",
      "snippet": "A drug safety group has delivered a positive analysis for a Sarepta-licensed RNA medicine, with the same study also hitting an enrollment target. The latter development has triggered a $200 milestone payment due to Arrowhead Pharmaceuticals.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "zsUueBfk",
      "url": "https://www.fiercebiotech.com/biotech/gilead-hatches-400m-biobucks-deal-swedish-biotechs-trex1-cancer-program",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 24, 2025 12:04pm",
      "snippet": "Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in biobucks.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "jzZc1U_8",
      "url": "https://www.fiercebiotech.com/pharma/novos-shares-tumble-8-after-2-trial-misses-semaglutide-alzheimers-disease",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 24, 2025 11:08am",
      "snippet": "Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "LHuggrfm",
      "url": "https://www.fiercebiotech.com/biotech/versants-dayra-dawns-50m-biogen-pact-oral-macrocyclic-peptide-mission",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 24, 2025 10:29am",
      "snippet": "VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen.",
      "kind": "competitive",
      "category": "competitive",
      "priority": 0.45,
      "assigned_to": "CRO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "FlXpt0Dg",
      "url": "https://www.fiercebiotech.com/biotech/jjs-5b-alzheimers-hope-fades-anti-tau-antibody-posdinemab-flops-phase-2",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 24, 2025 9:23am",
      "snippet": "Johnson &amp; Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to significantly slow clinical decline, prompting J&amp;J to stop the study.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "hFRHcTXj",
      "url": "https://www.fiercebiotech.com/biotech/fda-delays-decision-ascendis-dwarfism-prospect-3-months",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 26, 2025 9:21am",
      "snippet": "The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three months to buy time to review recently submitted information.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "B13pW8Kq",
      "url": "https://www.fiercebiotech.com/medtech/ceribell-scores-fda-nod-detecting-seizures-pre-term-newborns-and-older",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 26, 2025 7:56am",
      "snippet": "In what Ceribell described as a first, the FDA cleared its Clarity algorithm for detecting electrographic seizures in preterm infants as well as adults.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "-aZ8MDu_",
      "url": "https://www.fiercepharma.com/pharma/medicare-unveils-price-reductions-15-drugs-including-novos-semaglutide",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 26, 2025 11:05am",
      "snippet": "The U.S. has revealed price reductions for the second round of prescription drugs negotiated by Medicare through the Inflation Reduction Act (IRA). Headlining the list of 15 treatments that will undergo price reductions in 2027 are Novo Nordisk’s semaglutide products, Ozempic and",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "3viHH2Iy",
      "url": "https://www.fiercepharma.com/pharma/novo-cashes-fda-national-priority-voucher-extra-speedy-review-high-dose-wegovy",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 26, 2025 10:53am",
      "snippet": "The company filed its bid for a 7.2 mg Wegovy formulation using its National Priority Voucher from the FDA, which promises to accelerate a regulatory review to around one to two months. ",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "mdGu_vqk",
      "url": "https://www.fiercepharma.com/pharma/ever-more-crowded-kidney-disease-space-otsuka-receives-fda-approval-first-class-voyxact",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 26, 2025 10:50am",
      "snippet": "A new FDA approval for a first-in-class drug has vaulted Otsuka into the IgAN disease space, an increasingly competitive field targeted by multiple biopharma companies such as Novartis and Vertex.",
      "kind": "regulatory",
      "category": "regulatory",
      "priority": 0.55,
      "assigned_to": "CCO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "near-term"
    },
    {
      "id": "dOT9qHtH",
      "url": "https://www.fiercebiotech.com/biotech/ai-may-be-key-reigniting-vc-interest-biotech-pitchbook",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 26, 2025 10:35am",
      "snippet": "Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines.",
      "kind": "technology",
      "category": "technology",
      "priority": 0.35,
      "assigned_to": "COO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "SOCCNeVq",
      "url": "https://www.fiercebiotech.com/biotech/vaccine-focused-valneva-shutters-site-efforts-consolidate-rd-eliminating-30-roles",
      "title": "[object Object]",
      "source": "www.fiercebiotech.com",
      "published_at": "Nov 26, 2025 12:39pm",
      "snippet": "French vaccine maker Valneva is closing down a site that houses both operational and R&amp;D work, impacting 30 employee roles.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    },
    {
      "id": "n01jWtVp",
      "url": "https://www.fiercepharma.com/biotech/vaccine-focused-valneva-shutters-site-efforts-consolidate-rd-eliminating-30-roles",
      "title": "[object Object]",
      "source": "www.fiercepharma.com",
      "published_at": "Nov 26, 2025 12:39pm",
      "snippet": "French vaccine maker Valneva is closing down a site that houses both operational and R&amp;D work, impacting 30 employee roles.",
      "kind": "market",
      "category": "market",
      "priority": 0.4,
      "assigned_to": "CEO",
      "high_priority": false,
      "keyword_matches": 0,
      "impact": "low",
      "urgency": "long-term"
    }
  ],
  "last_run_at": "2025-11-28T23:38:12.336Z"
}